AU2018247249B2 - Therapeutic compositions for treating pancreatic cancer - Google Patents
Therapeutic compositions for treating pancreatic cancer Download PDFInfo
- Publication number
- AU2018247249B2 AU2018247249B2 AU2018247249A AU2018247249A AU2018247249B2 AU 2018247249 B2 AU2018247249 B2 AU 2018247249B2 AU 2018247249 A AU2018247249 A AU 2018247249A AU 2018247249 A AU2018247249 A AU 2018247249A AU 2018247249 B2 AU2018247249 B2 AU 2018247249B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- gemcitabine
- paclitaxel
- study
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 75
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 67
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 65
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title abstract description 55
- 230000001225 therapeutic effect Effects 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 229960005277 gemcitabine Drugs 0.000 claims description 103
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 101
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 94
- 229960001592 paclitaxel Drugs 0.000 claims description 90
- 229930012538 Paclitaxel Natural products 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 39
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 238000009169 immunotherapy Methods 0.000 claims description 16
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 15
- 229960001433 erlotinib Drugs 0.000 claims description 15
- 239000002207 metabolite Substances 0.000 claims description 15
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 14
- 229960004768 irinotecan Drugs 0.000 claims description 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 11
- 229960002949 fluorouracil Drugs 0.000 claims description 11
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 229960001756 oxaliplatin Drugs 0.000 claims description 10
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 description 93
- 238000011282 treatment Methods 0.000 description 93
- 206010028980 Neoplasm Diseases 0.000 description 80
- 210000004027 cell Anatomy 0.000 description 59
- -1 cyclohexanone compound Chemical class 0.000 description 56
- 229940079593 drug Drugs 0.000 description 56
- LJTSIMVOOOLKOL-FNRDIUJOSA-N antroquinonol Chemical compound COC1=C(OC)C(=O)[C@H](C)[C@@H](C\C=C(/C)CC\C=C(/C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-FNRDIUJOSA-N 0.000 description 40
- LJTSIMVOOOLKOL-KCZVDYSFSA-N antroquinonol Natural products COC1=C(OC)C(=O)[C@H](C)[C@@H](CC=C(/C)CCC=C(/C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-KCZVDYSFSA-N 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 229940044683 chemotherapy drug Drugs 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 24
- 238000009472 formulation Methods 0.000 description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 18
- 230000034994 death Effects 0.000 description 18
- 231100000517 death Toxicity 0.000 description 18
- 230000001472 cytotoxic effect Effects 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000002648 combination therapy Methods 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 231100000002 MTT assay Toxicity 0.000 description 13
- 238000000134 MTT assay Methods 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 11
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 11
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000001394 metastastic effect Effects 0.000 description 10
- 239000003381 stabilizer Substances 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 206010061818 Disease progression Diseases 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 230000005750 disease progression Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 9
- 231100000682 maximum tolerated dose Toxicity 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical class O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 8
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 239000002285 corn oil Substances 0.000 description 6
- 235000005687 corn oil Nutrition 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 229960000235 temsirolimus Drugs 0.000 description 6
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 6
- 230000001875 tumorinhibitory effect Effects 0.000 description 6
- 241000123370 Antrodia Species 0.000 description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229960004117 capecitabine Drugs 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 238000009533 lab test Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000037821 progressive disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 4
- LJTSIMVOOOLKOL-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCC=C(C)C)C1O LJTSIMVOOOLKOL-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229960000684 cytarabine Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 229960003881 letrozole Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229960005079 pemetrexed Drugs 0.000 description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 231100000279 safety data Toxicity 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 231100000402 unacceptable toxicity Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 102000003849 Cytochrome P450 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229940126602 investigational medicinal product Drugs 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- LJTSIMVOOOLKOL-JAXLGGSGSA-N antroquinonolTM Natural products COC1=C(OC)C(=O)[C@@H](C)[C@H](CC=C(C)CCC=C(C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-JAXLGGSGSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229960002412 cediranib Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000011498 curative surgery Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 201000008865 drug-induced hepatitis Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- 229950008209 gedatolisib Drugs 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 2
- 229950009158 tipifarnib Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- XDLYKKIQACFMJG-UHFFFAOYSA-N 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1C1CCC(OCCO)CC1 XDLYKKIQACFMJG-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 229940127124 90Y-ibritumomab tiuxetan Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000198601 Meripilaceae Species 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000486439 Photedes Species 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 231100000602 cytoskeletal drug Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000019016 inability to swallow Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000034839 mitotic sister chromatid segregation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920004905 octoxynol-10 Polymers 0.000 description 1
- 229920004914 octoxynol-40 Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001150 spermicidal effect Effects 0.000 description 1
- 230000007046 spindle assembly involved in mitosis Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention is directed to therapeutic compositions for treating pancreatic
cancer comprising a cyclohexnone compound and one or more anti-cancer agents.
Description
Field of the Invention
[0001a] The present invention relates to compositions for treating pancreatic cancer in a subject. Although the present invention will be described hereinafter with reference to its preferred embodiment, it will be appreciated by those of skill in the art that the spirit and scope of the invention may be embodied in many other forms.
Background of the Invention
[0001b] Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
[0001c] Pancreatic cancer arises when cells in the pancreas begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. Pancreatic cancer is the fourth leading cause of cancer death in Western countries and is also the tenth leading cause of cancer death in Taiwan. Approximately 60 percent of pancreatic cancer arises in the head of pancreas, and about 21 percent invades to whole pancreas.
[0001d] Pancreatic cancer can be divided into two general groups. The vast majority of cases, about 99%, occur in the part of the pancreas which produces digestive enzymes, known as the exocrine component. There are several sub-types of exocrine pancreatic cancers, but their diagnosis and treatment have much in common. These small minority of cancers arise in the hormone-producing (endocrine) tissue of the pancreas.
[0002] Surgery with the intention of a cure is only possible in around one-fifth (20%) of new cases. Although CT scans help, in practice, it can be difficult to determine whether the tumor can be fully removed (its "resectability"), and it may only become apparent during surgery that it is not possible to successfully remove the tumor without damaging other vital tissues. Even when the operation appears to have been successful, cancerous cells are often found around the edges ("margins") of the removed tissue. After surgery, adjuvant chemotherapy with gemcitabine or 5 FU can be offered if the person is sufficiently fit, after a recovery period of one to two months. In people not suitable for curative surgery, chemotherapy may be used to extend life or improve its quality of life.
[0002a] It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
[0002b] Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".
[0002c] Although the invention will be described with reference to specific examples it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.
Summary of the Invention
[0002d] According to a first aspect of the invention there is provided a method for treating pancreatic cancer in a subject comprising administering to the subject a compound having the structure:
CH 3 CH 3 CH 3 CH 3 0 CH 3 H 3CsO OH O sO 0 "CH 3
and one or more anti-cancer agents to wherein the one or more anti-cancer agents is erlotinib, 5-FU, oxaliplatin, irinotecan, gemcitabine, paclitaxel, or a combination thereof, or a pharmaceutically acceptable salt thereof.
[0002e] According to a second aspect of the invention there is provided use of a therapeutically effective amount of a compound having the structure:
CH 3 CH 3 CH 3 CH 3 0 /CH 3
H3Cs0 OH 0 'CH 3
or a pharmaceutically acceptable salt, thereof, in the manufacture of a medicament for treating a patient whose pancreatic cancer is resistant, refractory or non-responsive to gemcitabine, paclitaxel, or a combination thereof.
[0003] In one form provided herein are composition for treating pancreatic cancer in a subject R3 CH 3 O0 R4 n R1,X OR Ys1 comprising a compound having the structure: R2 and one or more anti cancer agents, wherein each of X and Y independently is oxygen, or sulfur; R is a hydrogen or C(=)C-C 8 alkyl;
each of R 1, R2 and R 3 independently is a hydrogen, methyl or (CH 2)m-CH3 ; R4 is H, CI-C8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or aryl optionally substituted with one
or more substituents selected from CI-C8 alkyl, C 2 -C8 alkenyl, C 2 -C8 alkynyl, C -C 3 8
cycloalkyl, and C1-C8 haloalkyl; n=1-12; or a pharmaceutically acceptable salt,
metabolite, solvate or prodrug thereof.
[0004] In another form provided herein are methods for treating pancreatic cancer in a subject comprising administering the subject in need thereof of a compound having the structure: R3 CH 3 O0 R4 n R1,X OR Y-1 R2 and one or more anti-cancer agents,
wherein each of X and Y independently is oxygen, or sulfur; R is a hydrogen or C(=)C-C 8 alkyl;
each of R 1, R2 and R 3 independently is a hydrogen, methyl or (CH 2)m-CH3 ; R4 is H, CI-C8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or aryl optionally substituted with one
or more substituents selected from CI-C8 alkyl, C 2 -C8 alkenyl, C 2 -C8 alkynyl, C -C 3 8
cycloalkyl, and C1-C8 haloalkyl; n=1-12; or a pharmaceutically acceptable salt,
metabolite, solvate or prodrug thereof.
[0005] In another form provided herein are methods for the treatment of a patient whose pancreatic cancer is resistant, refractory or non-responsive to gemcitabine, paclitaxel, or a combination thereof, comprising administering to a patient in need thereof a compound having
R3 CH 3 O0 R4 n R1,X OR Y-1 the structure: R2 or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, wherein each of X and Y independently is oxygen, or sulfur; R is a hydrogen or C(=)C-C 8 alkyl; each of R 1, R2 and R 3 independently is a hydrogen, methyl or (CH 2 )m-CH3 ; R4is H, CI-C8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or aryl optionally substituted with one or more substituents selected from CI-C8 alkyl, C 2 -C8 alkenyl, C 2 -C8 alkynyl, C -C 3 8
cycloalkyl, and C-C haloalkyl; n=1-12; or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
Incorporation by Reference
[0006] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Brief Description of the Drawings
[0007] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0008] FIG. 1A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with exemplary compound 1 for (1A) 48 hours and (1B) 72 hours. MTT assay was used to measure cytotoxic activity.
3a
[0009] FIG. 2A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with Erlotinib for (2A) 48 hours and (2B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0010] FIG. 3A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with 5-FU for (3A) 48 hours and (3B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0011] FIG. 4A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with Gemcitabine for (4A) 48 hours and (4B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0012] FIG. 5A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with Irinotecan for (5A) 48 hours and (5B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0013] FIG. 6A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with Oxaliplatin for (6A) 48 hours and (6B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0014] FIG. 7A/B provide the results of cytotoxic activity in AsPC-1 pancreatic cancer cells treated with Paclitaxel for (7A) 48 hours and (7B) 72 hours. MTT assay was used to measure cytotoxic activity.
[0015] FIG. 8 shows the effect of Compound 1 with chemotherapy drugs, paclitaxel, gemcitabine, 5-FU, oxaliplatin, erlotinib or irinotecan on the cytotoxicity of AsPC-1 pancreatic cancer cell line for 48 hours. MTT assay was used to measure cytotoxic activity. Values are means of survival rate ±SEM. Different letters (a-e) denote significant difference (P< 0.05) for various treatments.
[0016] FIG. 9 shows the cytotoxic activity of Compound 1 with chemotherapy drugs, paclitaxel, gemcitabine, 5-FU, oxaliplatin, erlotinib and irinotecan, respectively. AsPC-1 pancreatic cancer cells were treated antroquinonol or combination formula for or 72 hours. MTT assay was used to measure cytotoxic activity. Values are means of survival rate ±SEM. Different letters (a-g) denote significant difference (P< 0.05) for various treatments.
[0017] FIG. 10A-C show the dose-effect for combination of Compound 1 (also known as antroquinonol, Aq) with paclitaxel (Px), gemcitabine (Ge) in pancreatic cancer cell lines. Plots indicated the Fa values of the treated of combination of antroquinonol with paclitaxel, antroquinonol with gemcitabine, antroquinonol plus paclitaxel and gemcitabine in AsPC-1 (1OA), CaPan-2 (1OB) and Panc-1 (1OC) pancreatic cancer cell lines. The x-axis represents the dose of drugs in mol/L and the y-axis represents Fa, the fraction of cell affected (growth inhibition).
[0018] FIG. 11A-C show the analysis results of the combinations by Compound 1 with paclitaxel, gemcitabine in pancreatic cancer cell lines for 72 hours. CI plots for the combination of antroquinonol (Aq) with paclitaxel (Px), antroquinonol with gemcitabine (Ge), antroquinonol plus paclitaxel and gemcitabine in AsPC-1 (11A), CaPan-2 (11B) and Panc-1 (I1C) pancreatic cancer cell lines. The x-axis represents Fa (fraction of cell affected) and the y-axis represents CI (combination index). CI = 1, < 1 and >1 indicates additive effect, synergism and antagonism, respectively.
[0019] FIG. 12 shows the results of the mice body weight changes during the test of antitumor activity by Compound 1 with chemotherapy drugs on AsPC-1 subcutaneous xenograft model.
[0020] FIG. 13 shows the effect of antitumor activity of Compound 1 plus chemotherapy drugs on AsPC-1 subcutaneous xenograft model. Weekly measurements of tumor size were made and the mean relative tumor volume was plotted as a function of time after the start of treatment. Each point was presented mean of tumor volume.
[0021] FIG. 14 shows the effect of Compound 1 plus chemotherapy drugs on AsPC-1 subcutaneous xenograft model. Percentage of tumor volume significantly decreased in treatment groups of Compound 1 contained combinations which compared with control group (TI, corn oil).
[0022] FIG. 15 shows the analysis results of the Tumor Growth Inhibition (TGI) percent of Compound 1 alone or with chemotherapy drugs, paclitaxel and gemcitabine, on the growth of AsPC-1 tumor volume. Each column was presented mean of tumor growth inhibition. Values are means ±SEM. Different superscripts denote significant difference (P < 0.05) between each treatment group.
[0023] FIG. 16 illustrates the comparison results of representative photo of AsPC-1 pancreatic tumor xenograft before and after treatment with Compound 1 and/or plus chemotherapy drugs, respectively.
[0024] FIG. 17 illustrates the comparison results of representative ultrasound images of AsPC-1 pancreatic tumor xenograft before and after treatment with Compound 1 and/or plus chemotherapy drugs, respectively.
[0025] FIG. 18A/B show the result s of the images (18A) and figures (18B) of excised tumors at the time of sacrifice from the subcutaneous AsPC-1 pancreatic tumor xenograft-bearing male nude mice after 28 days of treatments. ANOVA was used to analyze the statistical significance.* P < 0.05 is considered to be statistically significant when compared with control group (TI, corn oil group).
[0026] FIG. 19 shows the results of inhibitory effect of Compound 1 alone or with chemotherapy drugs, paclitaxel and gemcitabine, on the growth of AsPC-1 solid tumor. Each column was presented mean of tumor inhibitory rate (TIR). Values are means of TIR ±SEM. Different superscripts denote significant difference (P< 0.05) between each treatment group.
Detailed Description of the Invention
[0027] Surgery with the intention of a cure is only possible in around one-fifth (20%) of new cases. Although curative surgery no longer entails the very high death rates that occurred until the 1980s, a high proportion of people (about 30-45%) still have to be treated for a post operative sickness that is not caused by the cancer itself. The most common complication of surgery is difficulty in emptying the stomach. After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently fit, after a recovery period of one to two months. Gemcitabine was approved by the United States Food and Drug Administration (FDA) in 1997, after a clinical trial reported improvements in quality of life and a 5-week improvement in median survival duration in people with advanced pancreatic cancer. Chemotherapy using gemcitabine alone was the standard for about a decade, as a number of trials testing it in combination with other drugs failed to demonstrate significantly better outcomes.
[0028] The FOLFIRINOX chemotherapy regimen using four drugs was found more effective than gemcitabine, but with substantial side effects, and is thus only suitable for people with good performance status. This is also true of protein-bound paclitaxel (nab-paclitaxel), which was licensed by the FDA in 2013 for use with gemcitabine in pancreas cancer. However, the changes of the last few years have only increased survival times by a few months.
[0029] A method for treating pancreatic cancer in a subject comprising administering the subject in need thereof a cyclohexanone compound was reported in U.S. patent number 8,236,860. An exemplary compound, Antroquinonol was studied for treating pancreatic cancer using the orthotopic PANC-1 human pancreatic cancer xenograft model. Four groups of mice were treated with 30 mg/kg, 60 mg/kg, 90 mg/kg, and vehicle control, respectively. Treatment with antroquinonol at 30, 60, and 90 mg/kg produced an effective anti-tumor activity with statistically significant smaller mean tumor volumes and tumor weights in all three dosage levels compared to vehicle control. Although Antroquinonol was shown to be a good candidate as a drug to treat pancreatic cancer, there was no consideration to use it in any combination therapy.
[0030] However, it is found unexpectedly a synergistic effect existed in a combination therapy R3 CH 3 O0 R4 n R1,X OR Ys1 comprising a compound having the structure: R2 , and one or more anti-cancer agents, such as gemcitabine, paclitaxel, or a combination thereof provides synergistic effects compared with the mono therapy; wherein each of X and Y independently is oxygen, or sulfur; R is a hydrogen or C(=)C-C 8 alkyl;
each of R1, R2 and R 3 independently is a hydrogen, methyl or (CH 2 )m-CH3 ; R4 is H, C-C8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or aryl optionally substituted with one
or more substituents selected from CI-C8 alkyl, C2 -C8 alkenyl, C 2 -C8 alkynyl, C -C 3 8
cycloalkyl, and C1-C haloalkyl;
n=1-12; or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof. In some embodiments, such combination therapy further comprises administering an immunotherapy agent.
[0031] In some embodiments, provided herein are compositions for treating pancreatic cancer in R3 CH 3 O R4 n R1,X OR Ys1 a subject comprising a compound having the structure: R2 , and one or more anti-cancer agents, (see Examples 1-3). The cyclohexenone compounds, in some embodiments, are obtained from extracts of natural products and in some other embodiments, are prepared synthetically. See for example, U.S. patent No. 9365481.
[0032] In some embodiments, the one or more anti-cancer agents comprise gemcitabine, paclitaxel, idarubicin/cytarabine, etopside phosphate, gleevec (imatinib), temozolomide, bortezomib, letrozole, cetuximab, bevacizumab, nab-paclitaxel, docetaxel, erlotinib, pemetrexed, pemetrexed/carboplatin, paxlitaxel/carboplatin, letrozole/cyclophsphamide, temsirolimus, bevacizumab/temsirolimus, lpilimumab, RADOO1, Pazopanib, FOLFIRI, BKM120, GSK1120212, PF-05212384/irinotecan, AZD2171, PF-04691502, cyclophosphamide, cisplatin, cytarabine/daunorubcin, tersirolimus, erlotinib/temsirolimus, capecitabine, tamoxifen, bortezomib, trastuzumab, docetaxel/capecitabine, trastuzumab/tipifarnib, tipifamib/gemcitabline, tootecan, or combinations thereof. In certain embodiments, the one or more anti-cancer agent is gemcitabine, paclitaxel, or a combination thereof. In certain embodiments, the one or more anti cancer agent are the combination of gemcitabine and paclitaxel.
[0033] For example, paclitaxel is classified as a "plant alkaloid," a "taxane" and an "antimicrotubule agent." It is used to treat a number of types of cancer such as ovarian cancer, breast cancer, lung cancer, Kaposi sarcoma, cervical cancer, and pancreatic cancer. Albumin bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nano-particles. Paclitaxel is known to have some common side effects including nausea and vomiting, loss of appetite, change in taste, thinned or brittle hair, pain in the joints of the arms or legs lasting two to three days, changes in the color of the nails, and tingling in the hands or toes. Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs such as colchicine that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly.
[0034] Another exemplary anticancer drug, gemcitabine is a nucleoside analog used as chemotherapy to treat a number of types of cancer including breast cancer, ovarian cancer, non small cell lung cancer, pancreatic cancer, and bladder cancer. Common side effects include bone marrow suppression, liver and kidney problems, nausea, fever, rash, shortness of breath, and hair loss. Use during pregnancy will likely result in harm to the baby. Gemcitabine is in the nucleoside analog family of medication. It works by blocking the creation of new DNA, which results in cell death.
[0035] In some embodiments, there are provided methods for treating pancreatic cancer in a subject comprising administering the subject in need thereof the combination therapy compositions described herein. In some embodiments provide the use of a therapeutically effective amount of the combination therapy compositions described herein in the manufacture of a medicament for treating pancreatic cancer in a subject.
[0036] In some embodiments, there are provided methods for the treatment of a patient whose pancreatic cancer is resistant, refractory or non-responsive to gemcitabine, paclitaxel, or a combination thereof, comprising administering the patient in need thereof R3 CH 3 0 / 4 n RX I OR Ys a compound having the structure: R2 or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof. In some embodiments, the mtheods further comprise administering an immunotherapy agent. In some embodiments provide the use of a R3 CH 3 O0 R4 n Rs N X OR Y-1 therapeutically effective amount of a compound having the structure R2 or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, in the manufacture of a medicament for treating a patient whose pancreatic cancer is resistant, refractory or non responsive to gemcitabine, paclitaxel, or a combination thereof.
[0037] In certain embodiments, the cancer is resistant, refractory or non-responsive to a drug selected from gemcitabine, paclitaxel, idarubicin/cytarabine, etopside phosphate, gleevec, temozolomide, bortezomib, letrozole, cetuximab, bevacizumab, nab-paclitaxel, docetaxel, erlotinib, pemetrexed, pemetrexed/carboplatin, paxlitaxel/carboplatin, letrozole/cyclophsphamide, temsirolimus, bevacizumab/temsirolimus, lpilimumab, RADOO1, Pazopanib, FOLFIRI, BKM120, GSKI1120212, PF-05212384/irinotecan, AZD2171, PF 04691502, cyclophosphamide, cisplatin, cytarabine/daunorubcin, tersirolimus, erlotinib/temsirolimus, capecitabine, tamoxifen, bortezomib, trastuzumab, docetaxel/capecitabine, trastuzumab/tipifamib, tipifarnib/gemcitabline, tootecan, or combinations thereof. In certain embodiments, the cancer is resistant, refractory or non-responsive to gemcitabine or paclitaxel. In certain embodiments, the cancer is resistant, refractory or non responsive to a combination of gemcitabine and paclitaxel.
[0038] In some embodiments, the cyclohexenone compound having the structure R3 CH 3 O0 R4 n R1,X OR Y-s R2 is prepared synthetically or semi-synthetically from any suitable starting material. In other embodiments, the cyclohexenone compound is prepared by fermentation, or the like. For example, Compounds 1, 3 and 4 are isolated from organic solvent extracts or prepared synthetically or semi-synthetically. The non-limited exemplary compounds are illustrated below.
HO* 0 OH HO OH
HO OH O1- 4
[0039] In some embodiments, R is a hydrogen, C(=O)C 3 H 7 , C(=O)C 2 H5 , or C(=O)CH 3 .In some embodiments, R1 is a hydrogen or methyl. In certain embodiments, R2 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl. In some embodiments, R3 is a hydrogen, methyl, ethyl, propyl, butyl, pentyl or hexyl. In some embodiments, R4 is hydrogen. In some embodiments, R4 is C1 -C 8 alkyl, C 2 -C 8alkenyl, C2 -C 8alkynyl, or aryl, optionally substituted with one or more
substituents selected from CI-C8 alkyl, C 2 -C8 alkenyl, C 2 -C8 alkynyl, C 3 -C8 cycloalkyl, and C-C 8
haloalkyl. In certain embodiments, R4is CH 2CH=C(CH 3)2 . In certain embodiments, the CH 3 CH 3 CH 3 CH 3 0 CH 3 H3C OH
compound is CH 3
[0040] In some embodiments, the methods to treat pancreatic cancer described herein comprise administering an immunotherapy agent. The immunotherapy agent includes, without limitation, any living immune cell that can be administered to a patient, and/or antibodies specific for a target cell (e.g., a tumor cell such as pancreatic cancer cell). Preferably, the immunotherapy agent is an NK cell or a T cell, or a modification or derivative thereof.
Immunotherapy
[0041] Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
[0042] In some embodiments, the immunotherapy agent is an anti-cancer antibody. Non-limiting examples include trastuzumab (Herceptin®), bevacizumab (Avastin®), cetuximab (Erbitux®), panitumumab (Vectibix®), ipilimumab (Yervoy®), rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), 90 Y-ibritumomab tiuxetan (Zevalin®),1 3 11-tositumomab (Bexxar®), anti programmed-death 1 (anti-PD-1) antibody such as Nivolumab, Pembrolizumab, and the like.
Certain Pharmaceutical and Medical Terminology
[0043] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed. In this application, the use of "or" or "and" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0044] An "alkyl" group refers to an aliphatic hydrocarbon group. The alkyl group may be a saturated alkyl group (which means that it does not contain any carbon-carbon double bonds or carbon-carbon triple bonds) or the alkyl group may be an unsaturated alkyl group (which means that it contains at least one carbon-carbon double bonds or carbon-carbon triple bond). The alkyl moiety, whether saturated or unsaturated, may be branched, or straight chain.
[0045] The "alkyl" group may have 1 to 12 carbon atoms (whenever it appears herein, a numerical range such as "1 to 12 refers to each integer in the given range; e.g., "1 to 12 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 12 carbon atoms, although the present definition also covers the occurrence of the term"alkyl" where no numerical range is designated). The alkyl group of the compounds described herein may be designated as, "CI-C 12 alkyl", "C1-C8 alkyl" or similar designations. By way of example only, "Ci-C alkyl" indicates that there are one, two , three, four, five, six, seven or eight carbon atoms in the alkyl chain. In one aspect the alkyl is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl, neopentyl, hexyl, allyl, but-2-enyl, but-3-enyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like. In one aspect, an alkyl is a Ci-C8 alkyl.
[0046] The term "alkylene" refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. In one aspect, an alkylene is a CI-C12alkylene. In another aspect, an alkylene is a C1 Csalkylene. Typical alkylene groups include, but are not limited to, -CH 2 -, -CH(CH3 )-, -C(CH 3) 2 -CH 2CH 2-, -CH2CH(CH 3 )-, -CH2C(CH 3) 2-, -CH 2CH2 CH2-, -CH 2CH2 CH2CH 2-, and the like.
[0047] As used herein, the term "aryl" refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl rings are formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups are optionally substituted. In one aspect, an aryl is a phenyl or a naphthalenyl. In one aspect, an aryl is a phenyl. In one aspect, an aryl is a C-Cioaryl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). In one aspect, an arylene is a C-Cio arylene. Exemplary arylenes include, but are not limited to, phenyl-1,2-ene, phenyl-1,3-ene, and phenyl-1,4-ene.
[0048] The term "aromatic" refers to a planar ring having a delocalized -electron system containing 4n+2 x electrons, where n is an integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted. The term "aromatic" includes both carbocyclic aryl ("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or"heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
[0049] The term "halo" or, alternatively, "halogen" or "halide" means fluoro, chloro, bromo or iodo.
[0050] The term "alkenyl" as used herein, means a straight, branched chain, or cyclic (in which case, it would also be known as a "cycloalkenyl") hydrocarbon containing from 2-10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. The alkenyl group of the compounds described herein may be designated as, "C -Calkenyl", 2 "C 2 Csalkenyl" or similar designations. By way of example only, "C2-C8 alkenyl" indicates that there
are two , three, four, five, six, seven or eight carbon atoms in the alkenyl chain. In some embodiments, depending on the structure, an alkenyl group is a monoradical or a diradical (i.e., an alkenylene group). In some embodiments, alkenyl groups are optionally substituted. Illustrative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2 propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-cecenyl.
[0051] The term "alkynyl" as used herein, means a straight, branched chain, or cyclic (in which case, it would also be known as a "cycloalkynyl") hydrocarbon containing from 2-10 carbons and containing at least one carbon-carbon triple bond formed by the removal of four hydrogens. In some embodiments, depending on the structure, an alkynyl group is a monoradical or a diradical (i.e., an alkynylene group). The alkynyl group of the compounds described herein may be designated as, "C 2-Cialkynyl", "C 2 -C 8alkynyl" or similar designations. By way of example only,
"C2-Calkynyl" indicates that there are two, three, four, five, six, seven or eight carbon atoms in the alkynyl chain. In some embodiments, alkynyl groups are optionally substituted. Illustrative examples of alkynyl include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and the like.
[0052] The term "cycloalkyl" as used herein, means a monocyclic or polycyclic radical that contains only carbon and hydrogen, and includes those that are saturated, partially unsaturated, or fully unsaturated. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Representative examples of cyclic include but are not limited to, the following moieties:
<> 0, 0X,0
In some embodiments, depending on the structure, a cycloalkyl group is a monoradical or a diradical (e.g., a cycloalkylene group).
[0053] The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and "haloalkoxy" as used herein, include alkyl, alkenyl, alkynyl and alkoxy structures in which at least one hydrogen is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another. The terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine. In certain embodiments, haloalkyls are optionally substituted.
[0054] The term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
[0055] Antrodia is a genus of fungi in the family Meripilaceae. Antrodia species have fruiting bodies that typically lie flat or spread out on the growing surface, with the hymenium exposed to the outside; the edges may be turned so as to form narrow brackets. Most species are found in temperate and boreal forests, and cause brown rot.
[0056] The term "carrier," as used herein, refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.
[0057] The terms "co-administration" or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
[0058] The term "diluent" refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution.
[0059] The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
[0060] A "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. The term "active metabolite" refers to a biologically active derivative of a compound that is formed when the compound is metabolized. The term "metabolized," as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphydryl groups. Metabolites of the compounds disclosed herein are optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
[0061] The term "pharmaceutical combination" as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound (i.e., a cyclohexenone compound described herein) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound (i.e., a cyclohexenone compound described herein) and a co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
[0062] The term "pharmaceutical composition" refers to a mixture of a compound (i.e., a cyclohexenone compound described herein) with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to: intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
[0063] The term "subject" or "patient" encompasses mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one embodiment, the mammal is a human.
[0064] The terms "treat," "treating" or "treatment," as used herein, include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
Routes of Administration and Dosage
[0065] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
[0066] In certain embodiments, a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation. In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically.
[0067] In some embodiments, the cyclohexenone compound, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, is administered parenterally or intravenously. In other embodiments, the cyclohexenone compound, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, is administered by injection. In some embodiments, the cyclohexenone compound, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, is administered orally.
[0068] In the case wherein the patient's condition does not improve, upon the doctor's discretion the administration of the compounds may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition. In the case wherein the patient's status does improve, upon the doctor's discretion the administration of the compounds may be given continuously or temporarily suspended for a certain length of time (i.e., a "drug holiday").
[0069] The foregoing ranges are merely suggestive, as the number of variables in regard to an individual treatment regime is large, and considerable excursions from these recommended values are not uncommon. Such dosages may be altered depending on a number of variables, not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
[0070] Toxicity and therapeutic efficacy of such therapeutic regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, for determining the LD5 o (the dose lethal to 50% of the population) and the ED5 o (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LDo and ED 5 o. Compounds exhibiting high therapeutic indices are preferred. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 5 owith minimal toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. In certain embodiments, the CH 3 CH 3 CH 3 CH 3 O CH 3 H 3CsI.. O O OH cyclohexenone compound is CH3 1 CH 3 CH 3 CH 3 CH 3 CH 3 CH3 CH 3 CH 3 O 0 CH 3 3 CH 3 H3C OH HO OH SOO SCH33 ,1 CH3 or CH 3 CH 3 CH 3 CH 3 O /CH 3 H3CO OH OH
[0071] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. In specific embodiments, pharmaceutical compositions are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients are used as suitable to formulate the pharmaceutical compositions described herein: Remington: The Science and PracticeofPharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's PharmaceuticalSciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., PharmaceuticalDosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical DosageForms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins1999).
[0072] Provided herein are pharmaceutical compositions comprising a compound (i.e., a cyclohexenone compound described herein) and a pharmaceutically acceptable diluent(s), excipient(s), or carrier(s). In certain embodiments, the compounds described are administered as pharmaceutical compositions in which a compound (i.e., a cyclohexenone compound described herein) is mixed with other active ingredients, as in combination therapy. Encompassed herein are all combinations of actives set forth in the combination therapies section below and throughout this disclosure. In specific embodiments, the pharmaceutical compositions include one or more compounds (i.e., a cyclohexenone compound described herein).
[0073] A pharmaceutical composition, as used herein, refers to a mixture of a compound (i.e., a cyclohexenone compound described herein) with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. In certain embodiments, the pharmaceutical composition facilitates administration of the compound to an organism. In some embodiments, practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds (i.e., a cyclohexenone compound described herein) are administered in a pharmaceutical composition to a mammal having a disease or condition to be treated. In specific embodiments, the mammal is a human. In certain embodiments, therapeutically effective amounts vary depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds described herein are used singly or in combination with one or more therapeutic agents as components of mixtures.
[0074] In one embodiment, a compound (i.e., a cyclohexenone compound described herein) is formulated in an aqueous solution. In specific embodiments, the aqueous solution is selected from, by way of example only, a physiologically compatible buffer, such as Hank's solution, Ringer's solution, or physiological saline buffer. In other embodiments, a compound (i.e., a cyclohexenone compound described herein) is formulated for transmucosal administration. In specific embodiments, transmucosal formulations include penetrants that are appropriate to the barrier to be permeated. In still other embodiments wherein the compounds described herein are formulated for other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions. In specific embodiments, such solutions include physiologically compatible buffers and/or excipients.
[0075] In another embodiment, compounds described herein are formulated for oral administration. Compounds described herein, including a compound (i.e., a cyclohexenone compound described herein), are formulated by combining the active compounds with, e.g., pharmaceutically acceptable carriers or excipients. In various embodiments, the compounds described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like.
[0076] In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipients with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0077] In one embodiment, dosage forms, such as dragee cores and tablets, are provided with one or more suitable coating. In specific embodiments, concentrated sugar solutions are used for coating the dosage form. The sugar solutions, optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs and/or pigments are also optionally added to the coatings for identification purposes. Additionally, the dyestuffs and/or pigments are optionally utilized to characterize different combinations of active compound doses.
[0078] In certain embodiments, therapeutically effective amounts of at least one of the compounds described herein are formulated into other oral dosage forms. Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules contain the active ingredients in admixture with one or more filler. Fillers include, by way of example only, lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In other embodiments, soft capsules, contain one or more active compound that is dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added.
[0079] In other embodiments, therapeutically effective amounts of at least one of the compounds described herein are formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels. In still other embodiments, the compounds described herein are formulated for parental injection, including formulations suitable for bolus injection or continuous infusion. In specific embodiments, formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers. Preservatives are, optionally, added to the injection formulations. In still other embodiments, the pharmaceutical compositions of a compound (i.e., a cyclohexenone compound described herein) are formulated in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles. Parenteral injection formulations optionally contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In specific embodiments, pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. In additional embodiments, suspensions of the active compounds are prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, by way of example only, fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. In certain specific embodiments, aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension contains suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, in other embodiments, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0080] In one aspect, compounds (i.e., cyclohexenone compounds described herein) are prepared as solutions for parenteral injection as described herein or known in the art and administered with an automatic injector. Automatic injectors, such as those disclosed in U.S. Patent Nos. 4,031,893, ,358,489; 5,540,664; 5,665,071, 5,695,472 and WO/2005/087297 (each of which are incorporated herein by reference for such disclosure) are known. In general, all automatic injectors contain a volume of solution that includes a compound (i.e., a cyclohexenone compound described herein) to be injected. In general, automatic injectors include a reservoir for holding the solution, which is in fluid communication with a needle for delivering the drug, as well as a mechanism for automatically deploying the needle, inserting the needle into the patient and delivering the dose into the patient. Exemplary injectors provide about 0.3 mL, 0.6mL, 1.OmL or other suitable volume of solution at about a concentration of 0.5 mg to 50 mg of a compound (i.e., a cyclohexenone compound described herein) per 1 mL of solution. Each injector is capable of delivering only one dose of the compound.
[0081] In still other embodiments, the compounds (i.e., cyclohexenone compounds described herein) are administered topically. The compounds described herein are formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0082] In still other embodiments, the compounds (i.e., cyclohexenone compounds described herein) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
[0083] In certain embodiments, pharmaceutical compositions are formulated in any conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any pharmaceutically acceptable techniques, carriers, and excipients is optionally used as suitable and as understood in the art. Pharmaceutical compositions comprising a compound (i.e., a cyclohexenone compound described herein) may be manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0084] Pharmaceutical compositions include at least one pharmaceutically acceptable carrier, diluent or excipient and at least one compound (i.e., cyclohexenone compounds described herein) described herein as an active ingredient. The active ingredient is in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use crystalline forms (also known as polymorphs), as well as active metabolites of these compounds having the same type of activity. All tautomers of the compounds described herein are included within the scope of the compounds presented herein. Additionally, the compounds described herein encompass unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein. In addition, the pharmaceutical compositions optionally include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, buffers, and/or other therapeutically valuable substances.
[0085] Methods for the preparation of compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid or liquid. Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories. Liquid compositions include solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein. Semi-solid compositions include, but are not limited to, gels, suspensions and creams. The form of the pharmaceutical compositions described herein include liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions also optionally contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and so forth.
[0086] In some embodiments, pharmaceutical composition comprising at least compound (i.e., cyclohexenone compounds described herein) illustratively takes the form of a liquid where the agents are present in solution, in suspension or both. Typically when the composition is administered as a solution or suspension a first portion of the agent is present in solution and a second portion of the agent is present in particulate form, in suspension in a liquid matrix. In some embodiments, a liquid composition includes a gel formulation. In other embodiments, the liquid composition is aqueous.
[0087] In certain embodiments, pharmaceutical aqueous suspensions include one or more polymers as suspending agents. Polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross linked carboxyl-containing polymers. Certain pharmaceutical compositions described herein include a mucoadhesive polymer, selected from, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
[0088] Pharmaceutical compositions also, optionally include solubilizing agents to aid in the solubility of a compound (i.e., cyclohexenone compounds described herein). The term "solubilizing agent" generally includes agents that result in formation of a micellar solution or a true solution of the agent. Certain acceptable nonionic surfactants, for example polysorbate 80, are useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.
[0089] Furthermore, pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
[0090] Additionally, pharmaceutical compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
[0091] Other pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
[0092] Still other pharmaceutical compositions include one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
[0093] Still other pharmaceutical compositions may include one or more antioxidants to enhance chemical stability where required. Suitable antioxidants include, by way of example only, ascorbic acid and sodium metabisulfite.
[0094] In certain embodiments, pharmaceutical aqueous suspension compositions are packaged in single-dose non-reclosable containers. Alternatively, multiple-dose reclosable containers are used, in which case it is typical to include a preservative in the composition.
[0095] In alternative embodiments, other delivery systems for hydrophobic pharmaceutical compounds are employed. Liposomes and emulsions are examples of delivery vehicles or carriers herein. In certain embodiments, organic solvents such as N-methylpyrrolidone are also employed. In additional embodiments, the compounds described herein are delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials are useful herein. In some embodiments, sustained-release capsules release the compounds for a few hours up to over 24 hours. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
[0096] In certain embodiments, the formulations described herein include one or more antioxidants, metal chelating agents, thiol containing compounds and/or other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
General Consideration for Combination Treatments
[0097] In general, the compositions described herein and, in embodiments where combinational therapy is employed and described herein, other agents do not have to be administered in the same pharmaceutical composition, and in some embodiments, because of different physical and chemical characteristics, are administered by different routes. In some embodiments, the initial administration is made according to established protocols, and then, based upon the observed effects, the dosage, modes of administration and times of administration is modified by the skilled clinician.
[0098] In some embodiments, therapeutically-effective dosages vary when the drugs are used in treatment combinations. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient. For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease, disorder, or condition being treated and so forth.
[0099] It is understood that in some embodiments, the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in other embodiments, the dosage regimen actually employed varies widely and therefore deviates from the dosage regimens set forth herein.
Examples Example 1. Preparation of the exemplary cyclohexenone compounds
[00100] Via a particular herbal purification procedure: the following procedure is for illustration purposed only. The other purification methods may be used as well.
[00101] One hundred grams of mycelia, fruiting bodies or mixture of both from Antrodia camphoratawere placed into a flask. A proper amount of water and alcohol (70-100% alcohol solution) was added into the flask and were stirred at 20-25° C for at least 1 hour. The solution was filtered through a filter and 0.45 m membrane and the filtrate was collected as the extract.
[00102] The filtrate of Antrodia camphoratawas subjected to High Performance Liquid chromatography (HPLC) analysis. The separation was performed on a RP18 column, the mobile phase consisted of methanol (A) and 0.3% acetic acid (B), with the gradient conditions of 0-10 min in 95% - 20% B, 10-20 min in 20%-10% B, 20-35 min in 10%-10% B, 35-40 min in 10% % B, at the flow rate of1 ml/min. The column effluent was monitored with a UV-visible detector.
[00103] The fractions collected at 25 to 30 min were collected and concentrated to yield 4 hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-enone (compound 1), a product of pale yellow brown liquid. The analysis of compound 1 showed the molecular formula of C 24 H 3804, molecular weight of 390 with melting point of 48 to 52 °C. NMR spectra showed that1H-NMR (CDCl3 ) 6 (ppm)=1.51, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.07, and 5.14;1 3 C-NMR (CDCl 3 ) 6 (ppm)=12.31, 16.1, 16.12, 17.67, 25.67, 26.44, 26.74, 27.00, 39.71, 39.81, 40.27, 43.34, 59.22, 60.59, 120.97, 123.84, 124.30, 131.32, 135.35, 135.92, 138.05, 160.45, and 197.12. CH 3 CH 3 CH 3 CH 3 0 /CH 3
H3C OH
CH 3 1 Compound1:4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10 trienyl)cyclohex-2-enone Other compounds where R4 is H, C-Calkyl, C 2-Csalkenyl, C 2-Csalkynyl, or aryl optionally substituted with one or more substituents selected from C-C1 alkyl, C 2-C, alkenyl, C2-C alkynyl, C 3-C 8 cycloalkyl, and C1-C haloalkyl were obtained as well.
[00104] Alternatively, the exemplary compounds may be prepared synthetically. See for example, U.S. Patent No. 9365481. R3 CH 3 O0 R4 n R1,X OR Ys1 Similarly, other cyclohexenone compounds having the structure R2 are isolated from Antrodia camphorataor prepared synthetically or semi-synthetically from the suitable starting materials. An ordinary skilled in the art would readily utilize appropriate conditions for such synthesis. Example 2. Study of Compound 1 with clinical chemotherapy drugs on human pancreatic carcinoma in AsPC-1 Cell Culture System and in a Severe Combined Immunodeficient Mouse Xenograft Tumor Model
[00105] In order to evaluate the efficacy of a combination therapy comprising the exemplary compound 1 with an anticancer agent (e.g., any clinically used drugs) for the treatment of pancreatic carcinoma development, an in vitro study and an in vivo xenografts study by an exemplary Compound 1 with selected current clinical chemotherapy drugs were conducted.
[00106] For in vitro study, Compound 1 and each of the selected six (6) clinical chemotherapy drugs were used on human pancreatic carcinoma AsPC-1 and/or CaPan-2, PANC 1 in cell culture system.
[001071 In in vivo xenograft mouse model, gemcitabine and/or paclitaxel were selected to be administered via tail vein twice a week with an oral administration of Compound 1 once a day for a total of 28 doses on human pancreatic carcinoma AsPC-1 xenograft model.
[00108] In Vitro Test:
[00109] The human pancreatic carcinoma cell lines, AsPC-1, PANC-1 and CaPan-2 were seeded 3 x 10 4 cells per well and cultured in a forty-eight (48) well cell culture dish (growth area 0.95 cm2 per well). Sixteen (16) hours later, cells were treated Compound 1 alone or Compound 1 with a clinical chemotherapy drug, respectively. After 48 or 72 hours of the treatment, methylthiazoletetrazolium (MTT) assay (supplemental protocol-1) was performed to measure the effect of treatment on the viability of cells during proliferation.
[00110] In vivo Test:
[00111] The human pancreatic carcinoma cell line, AsPC-1, was cultured and the cells were injected subcutaneously in a flank of 60 mice. Three days later, the tumors could be felt in the mice. When tumors reached approximately 100-200 mg (mm 3), total of fifty one (51) tumor bearing mice were randomly selected and sorted into one of six (6) groups. Vehicle (corn oil) treated mice were used as negative controls. Compound 1 combined with gemcitabine or paclitaxel were administered orally once a day and/or I.V. twice a week for four (4) weeks. Tumor measurements were recorded once a week using hand-held calipers and Visualsonic Vevo 2100 image system. Individual mouse weights were taken once a week during dosing. Mice were monitored daily for signs of toxicity and morbidity; any abnormal findings were recorded. The study was terminated four (4) weeks after initiation of drug administration.
[001121 Mice were euthanized when an individual mouse has a tumor that is 2,000 mg (cm 3) over one (1) measurement. A mouse was moribund when a tumor impedes the mouse's ability to feed, drink or ambulate, or if a mouse loses >20% of its original body weight. An individual group was euthanized when tumors reached a mean target size of 1,500 mg per group over two (2) consecutive measurements. The study coordinators should be notified of any unscheduled euthanasia. The study was terminate four (4) weeks after the initiation of drugs administration.
Test System:
[00113] A. Cell Lines: Human pancreatic carcinoma AsPC-1 (ATCC Catalog No. CRL-1682). Human pancreatic carcinoma PANC-1 (ATCC Catalog No. CRL-1469). Human pancreatic carcinoma CaPan-2 (ATCC Catalog No. HTB-80).
[00114] B. Cell Preparation 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 5 mL HBSS. Gently shake and remove the HBSS. 3. Add 5 mL trypsin-EDTA to 15 cm2 polystyrene dishes. Incubate 5 mins at 37C in a humidified incubator with 95% air / 5% C02 atmosphere. 4. Add 5 mL of complete growth medium (DMEM medium containing 10% FBS) and aspirate cells by gently pipetting. 5. Count live cells using the trypan blue exclusion assay (supplemental protocol 2) with a hemocytometer. 6. For in vitro study, cells will be seeded 3 x 104 cells per well and cultured in a forty-eight (48) wells cell culture dish for sixteen (16) hours until treatment. 7. Incubate cultures at 37C.
[00115] C. Animal Species/Strain: a. Nude mice, BALB/cAnN.Cg-Foxn ""/CrlNarl b. Female, athymic nude mice (nu/nu) 4-6 wk of age. c. Body weight: between 15 and 20 g on the day of inoculation of tumor cells.
[00116] D. Human pancreatic carcinoma xenograft models: 1. To create the subcutaneous xenograft model, athymic female nude mice (4-6 weeks old) were subcutaneously inoculated with 1 X 107 AsPC-1 cells in 0.1 mL of serum-free DMEM medium containing 20% Matrigel (BD Biosciences,
Bedford MA). 2. Tumor-bearing animals were divided into the following 6 groups as table 1. 3. The mice were monitored for activity and physical condition every day, and the determination of body weight and measurement tumor mass should be done once a week. Tumor image will be photed by digital camera and Visualsonic Vevo 2100 image system. Tumor mass is determined by caliper measurement in two perpendicular diameters of the implant and calculate using the formula (4/3)X(nXaXb 2 ), where "a" stands for the long diameter and "b" is the short diameter.
[001171 E. Test Articles:
[00118] The clinical chemotherapy drugs were purchased from Sigma-Aldrich Co. LLC, and prepared in the following manner: - Erlotinib (Stock conc. 100 mM in DMSO, Sigma Cat.# E4997). - 5-Fluorouracil (Stock conc. 100 mM, Sigma Cat.# F6627). - Gemcitabine (Stock conc. 100 mM in DMSO, Sigma Cat.# G6423). - Irinotecan (Stock conc. 100 mM in DMSO, Sigma Cat.# 11406). - Oxaliplatin (Stock conc. 50 mM in DMSO, Sigma Cat.# 09512). - Paclitaxel (Stock conc. 10 mM in DMSO, Sigma Cat.# T7402).
[00119] For in vivo test, gemcitabine (G) was purchased from Eli Lilly (Indianapolis, IN, USA), and paclitaxel (P) was purchased from Sigma-Aldrich.
[00120] F. in vitro experiment design:
[00121] a. Cytotoxicity of test articles (TC 5 ): AsPC-1 was seeded 3 x 104 cells (counted by Cell counter, LUNATM Automated Cell Counter or hemocytometer) per well and cultured in a 48 wells cell culture dish. Cells were treated with single article from 400 or 800 M with serial dilution to 0 M. After 48 or 72 hours of treated, MTT assay was performed to measure the effect of treatment on the viability of AsPC-1 cells during proliferation. The absorbance at 595 nm was measured using a microplate reader (BioTEK, Synergy TM HI). Article sensitivity curves and TC5 o values were calculated using GraphPad Prism 4.0 software.
[00122] b. Combination therapy of Compound 1 and chemotherapy drugs: This study also contains the cytotoxicity of Compound 1 plus a chemotherapy drug of selections to investigate the efficacy of such combination. Compound 1 combined each of paclitaxel, gemcitabine, 5-FU, oxaliplatin, erlotinib, and irinotecan, respectively. After treated 72 hours, MTT assay was performed to measure the effect of treatment on the viability of AsPC-1 cells during proliferation. The absorbance at 595 nm was measured using a microplate reader.
[001231 c. Evaluation of drug interactions: MTT assay was also performed to test the effect of drug combinations on the viability of AsPC-1, PANC-1 and CaPan-2 cell lines. The combination index (CI) isobologram method of Chou and Talalay (Chou and Talalay, 1984; Chang and Chou, 2000) which is based on the median-effect principle, was used to calculate synergism or antagonism for the combined drug effects. Dose-effect curves for each drug, separately and in combination, in serially diluted concentrations were plotted using the median effect equation and plot (Chou, 1991) and the CI equation and plot (Chou et al., 1994). CI values at different effect and dose levels and isobolograms were generated automatically using the computer software CompuSyn (Chou and Martin, 2005). With this method, additive, synergistic, or antagonistic effects are indicated by CI values of 1, <1, and >1, respectively.
[00124] G. in vivo experiment design:
[00125] a. Cell Injections: Mice were injected subcutaneously into the right lateral thorax with 1 x 10' viable human pancreatic carcinoma AsPC-1 Cells. A total of 60 mice were injected, with approximately 36 tumor-bearing mice were used on this study.
[00126] b. Selections of animals and group Assignment: This study contained six (6) groups and each group included eight (8) or nine (9) mice respectively. When tumors reached a target window size of approximately 100-200 mg (mm3), 54 tumor-bearing mice were randomly selected and sorted into one of 6 groups. Groups 1 is a solvent treated negative control and contained mice receiving treatment-1. Group 2, 3, 4, 5 and 6 contained mice that received treatment -2, treatment -3, treatment -4, treatment-5 and treatment -6, respectively. Table 1 lists test articles concentrations, solvent articles and dosing schedule.
[001271 c. Dose preparation: c-1: Compound 1 (A) i. Weighed an appropriate amount of Compound 1 and added into a 50 mL tube. ii. Added an appropriated amount of corn oil (Sigma-Aldrich) into the 50 mL tube. Mixed the formulation with vortex until homogenized completely. Pulled the formulation up into a disposable syringe and transferred to 4 mL brown tubes, 3.2 mL / tube. iii. Stored the suspension at frozen conditions (-20°C) until used. iv. Completely thawed the formulation in a 37°C water bath on day of intended use. c-2: Gemcitabine (G) i. Stock of gemcitabine was stored as a 50 mg/mL solution in sterile PBS at -20°C (Ito et al., 2006; Awasthi et al., 2013). ii. Before animal studies, weighed an appropriate amount of gemcitabine into a 4 mL tube. iii. Added an appropriate volume of vehicle-I (50% Ethanol & 50% Tween-80 (v/w)) into the 4 mL tube and shook until the material dissolved completely. iv. Added an appropriate volume of physiological saline into the 4 mL tube and moved the tube side-by-side to completely homogenize the solution. c-3: Paclitaxel (P) i. Stock of paclitaxel was dissolved in 100% ethanol to final concentration 10 mg/mL (Shi et al., 2000; Chang et al., 2006; Awasthi et al., 2013). ii. Before animal studies, weighed an appropriate amount of paclitaxel into a 4 mL tube. iii. Added an appropriate volume of vehicle-Ibinto the 4 mL tube and shook until the material dissolved completely. iv. Added an appropriate volume of physiological saline into the 4 mL tube and moved the tube side-by-side to completely homogenize the solution.
[00128] Table 1: Treatment groups of AsPC-1 xenograft: Dose Group Treatment Dose/mouse/day or time Dosing Route volume / Frequency Number label mouse
1 Treatment -1 Solvent (corn oil) oral
2 Treatment -2 A (120 mg/kg) oral (A)
A (120 mg/kg) oral (A) / IV 3 Treatment -310pL Oal G (100 mg/kg) (G) A (120 mg/kg) oral (A) / IV for oral, once a day, 4 Treatment -4 20- 30 I.V. twice
G(100mg/kg) uL for weekly for 5 Treatment -5 IV (G & P) I.V. 4 weeks. P(5 mg/kg) G (10 mg/kg) oral(A) IV 6 Treatment -6 P (30 mg) A(120 mg/kg)
[00129] Observations and Examinations of in vivo system:
[00130] A. Clinical Observations: Clinical observations of each study animal were performed and at least once daily (including weekends and holidays) for signs of morbidity, mortality and Test Article toxicity. Morbidity includes signs of illness such as, but not limited to, emaciation, dehydration, lethargy, hunched posture, unkempt appearance, dyspnea and urine or fecal staining. All abnormal findings will be recorded.
[00131] B. Animal Weights: Individual animal weights were taken one (1) time per week after/before dosing. Weights were recorded first prior to cell injections and continued for the duration of the study.
[00132] C. Tumor Measurements: The injection site of each animal was monitored one (1) time per week for signs of tumor growth. Throughout the study, the length (a) and width (b) of any tumors developed were measured in millimeters (mm) using vernier calipers, where a is the longer of the two (2) dimensions. The applicable tumor size in millimeter (mm) or centimeter (cm) was calculated by using the formula associated with a prolate ellipsoid: M = (4/3) X (R X a X b 2 ); and these data was recorded.
[00133] D. Evaluation of drug synergistic effect by tumor growth inhibition (TGI) and tumor inhibitory ratio (TIR): Volume of tumor growth inhibition (TGI) for each group was calculated according to the following formula:
Tumor growth inhibition (%) = (1 - [T - To] / [C - Col) x 100
T and To are the mean tumor volumes on the end day and day1 of treatment, respectively, for the experimental groups. For the control groups, C and Co are the mean tumor volumes on a end day and the start of the study, respectively.
For TIR, at the 4th week after treatment, the mice were sacrificed, and tumors were ablated carefully and weighed after any remaining blood was washed off with PBS. The tumor inhibitory ratio was calculated by the formula:
Tumor inhibitory ratio (%) = R(WContro - WTreated)/ WControil x100%
WTreated and Wontrol are the average tumor weights of the treated and control mice, respectively.
[00134] D. Hematological parameters: Cardiac blood was collected in EDTA for analyzing hematological parameters such as white blood cell count (WBC), red blood cell count (RBC), hemoglobin concentration (HB), hematocrit, mean corpuscular hemoglobin and concentration, platelet distribution width, platelet count, neutrophils, lymphocytes, monocytes, eosinophils. This was determined using hematology counter (Abbott Cell-Dyn 3700, IL).
[001351 Statistical analysis: All data are presented as mean standard error of the mean (SEM). One-way analysis of variance (ANOVA) was used to determine significance between groups. For multiple comparisons of more than two groups, the ANOVA analysis was used and followed by post-hoc tests with the Bonferroni correction. A value of P < 0.05 was considered to be significant.
[00136] Illustration of daily schedule of xenograft study: AsPC-1 human pancreatic carcinoma cells injection schedule S
tl
Start
Dl D8 D151IzzztztI I f-z t 10l/9(Tue t 1st week I 2nd week :1 3rd week
: AsPC-1 human pancreatic carcinoma cells D22 D2I D2I implanted day :Administered oral -Treatment-1, Treatment-2, EndIV. Treatment-3, Treatment-4 and Treatment-6. :Injection day (IV) - Treatment-3, Treatment-4 and Treatment-6 4th week Tumor measurement and Body weight
[001371 Results:
[001381 In vitro cytotoxicity: To evaluate the combinatorial therapeutic efficiency of the exemplary compound 1, the viability of treated AsCp-1 cell lines using 3-(4,5-dimethylthiazol- 2 yl)-2,5-diphenyltetrazolium bromide (MTT) assay was measured. The toxic concentration (TCo) of Compound 1 (i.e., antroquinonol) and chemotherapy drugs on AsPC-1 cell line was investigated. FIGs. 1 to 7 and Table 2 show the cytotoxicity of Compound 1 and chemotherapy drugs on AsPC-1 cell line. According to these results, it was confirmed that compound 1 and combination treatment of chemotherapy drugs on AsPC-1 cell viability following by drug concentration on Table3. AsCP-1 cells were individually incubated with compound 1 or each of the drug combinations for 48 h and 72 h. In FIGs. 8 and 9, the viability of AsPC-1 cells incubated with Compound 1, MTT assays of each chemotherapy drug and their combinations for 48 h and 72 h respectively were measured. AsPC-1 cells treated with Compound 1 or chemotherapy drugs alone showed 75% to 80% viability after incubation for 48 h or 72 h. According to these results, the combination therapies of Compound 1 with the selected chemotherapy drugs may have a synergistic effect to control AsPC-1 cell viability. Moreover, these results also indicated a combination of the tested clinical drugs and Compound 1 has a more extreme effect on AsPC-1 human pancreatic cancer cells than the corresponding single drug treatment.
[00139] Table 2. Effect of anticancer drugs on cytotoxicity at 48 and 72 hours (Antroquinonol= Compound 1)
Drug TC5o (pM)a 48 hrs 72 hrs Antroquinonol 58.09 24.04 Erlotinib > 800 > 800 5-FU >800 >800 Gemcitabine > 800 > 800 Irinotecan 221.3 68.34 Oxaliplatin 654.7 57.91 Paclitaxel 7.054 3.719
aTC 5 : the concentration of the compound at which cell viability was reduced to 50%.
[00140] The combinations of Compound 1 with paclitaxel and/or gemcitabine, which have synergistic effect for pancreatic cancer were evaluated. Three pancreatic cancer cell lines, AsPC 1, CaPan-2 and Panc- Iwere used to test the combinations through median effect analysis.
[001411 Table 3. Drugs concentrations used in the combinations on cytoxicity of AsPC-1 cells.
Conc. (pM) Drug 48 hrs 72 hrs Antroquinonol 20 20 (Compound 1) Erlotinib 100 100 5-FU 100 100 Gemcitabine 100 100 Irinotecan 200 70 Oxaliplatin 200 60 Paclitaxel 7 3
[001421 Evaluation of the combination therapy effect of Compound 1 with chemotherapeutic drugs, gemcitabine and paclitaxel
[001431 The median effect analysis of Chou and Talalay (Chou and Talalay, 1984) was used to calculate the CI for each drug combination formula. Therefore, CI value was used to determine if there is a synergy effect between Compound 1 and gemcitabine, and/or paclitaxel in this study. In the AsPC-1, CaPan-2 and Panc-1 cell lines, the two or three compound combinations of Compound 1 with chemotherapy drugs, paclitaxel and gemcitabine, were strongly synergistic (CI < 1, FIG. 11) across the entire range of doses (e.g., see FIG. 10 and 11). These results presented that the exemplary compound (i.e., Compound 1) with a second or third currently used chemotherapeutic drugs strongly inhibit pancreatic cancer growth especially in the three compound combination. In vivo antitumor activity on AsPC-1 subcutaneous xenograft model
[00144] The antitumor activity of the combination therapy comprising the exemplary Compound 1 was assessed on AsPC-1 tumor bearing nude mice. AsPC-1 cells were subcutaneously injected 7 days before commencing treatment to the mice (Table 1). These animals then received daily administration of various drug combinations for 28 days. At day 28, all test mice were sacrificed and corresponding tumors were excised for further studies. As shown in FIGs. 13 and 14, at the end of the experiments, the mice treated with the combination of Compound 1 and gemcitabine (T3), or the combination of Compound 1, gemcitabine and paclitaxel (T6), showed a highly significant tumor regression with a slow growing in tumor volume. Mice in the other four treatment groups showed strict tumor growth comparing with groups T3 and T6. The tumor growth inhibition rate increased significantly in the combination of Compound 1 and gemcitabine (T3), or the combination of Compound 1, gemcitabine and paclitaxel (T6) (FIG. 15) compared with the groups (FIG. 16, T2, T4 and T5).
[00145] FIG. 17 illustrates the treatment results represented by the ultrasound images of AsPC-1 pancreatic tumor xenograft during the period of treatments. Photographs of the tumors from the sacrificed mice are shown in FIG. 18A. It can be seen that the tumor volumes in mice treated with Compound 1 and gemcitabine are significant smaller than those treated with other combinations. In particular, FIG. 18B shows that the tumor weight in the mice treated with Compound 1 and gemcitabine is much smaller as compared to those in other groups. All of these results demonstrate that the combination therapy described herein does have predominant tumor growth inhibitory efficacy. The tumor inhibitory rate (TRI) in each group was also calculated based on final tumor weights (FIG. 19). Tumor growth was inhibited significantly in the groups of Compound 1 plus gemcitabine (FIG. 19, T3), and Compound 1 plus the other two drugs (FIG. 19, T6).
[00146] In order to confirm that therapeutic efficacy of the combination therapy based on the exemplary compound 1 is much better than that of mono-chemotherapy drug, the synergistic effects of the selected drug combinations were evaluated by tumor volume of treatment-to control ratio (TCR), tumor growth inhibition (TGI) and tumor inhibitory ratio (TIR). In AsPC-1 xenografts, monotherapy of Compound 1 was able to inhibit tumor growth, with treatment-to control ratios (TCR) of 0.55. The combination of Compound 1 and gemcitabine (Table 4, Ge
+ Aq) produced a dramatically enhanced antitumor activity compared with the other mono or two compound combinations treatments (TCR 0.36; Table 4; Fig. 13). In the meantime, the combination with three medicines comprising Compound 1 (Table 4, Px + Ge + Aq) also induced strong antitumor activity compared with either mono or other combination therapies (TCR 0.46; Table 4; Fig. 13). According to those results, Compound 1 in combinations with gemcitabine, or with additional paclitaxel have enhanced antitumor activity, significantly.
[001471 In addition, no significant weight loss was observed in the tumor-bearing mice treated with various combinations, indicating negligible side effect of Compound 1 and other two chemotherapy drugs for tumor therapy at the employed doses (FIG. 12). Consistently, Compound 1 and its combinations did not affect number of blood cells except for blood glucose in AsPC-1 xenograft (Table 5.). According to these data, it suggests that Compound 1, and/or its combinations thereof have low safety risk of taking orally.
[00148] Table. 4. Tumor weight of excised tumors at the time of sacrifice from the subcutaneous AsPC-1 pancreatic tumor xenograft-bearing male nude mice after 28 days of treatments.
Treatment Groups#
TI T2 T3 T4 T5 T6
Tumor 0.42± 0.1la 0.21 0. 0 7b 0.11± 0.05 0 .2 2 0. 1 6b 0.31 0. 2 1 b 0 .2 4 0. 0 9b weight
#Six treatment groups of the mice administrated corn oil (TI), Compound 1 (T2), combination of Compound 1 and gemcitabine (T3), combination of Compound 1 and paclitaxel (T4), combination of gemcitabine and paclitaxel (T5) and combination of Compound 1, gemcitabine, and paclitaxel (T6).
- Tumor weights are means ±SEM. Values in the same row are followed by a different superscript (a-b) are significantly at P < 0.05.
[00149] Table 5. Synergistic antitumor activity by combinations of Compound 1 (Aq), paclitaxel (Px) and gemcitabine (Ge) in AsPC-I xenograft.
Xenograft Treatment Response, TCR TGI(%) TIR(%)
Control 1.00 -
Aq 0.55 51 45
Ge + Aq 0.36 73 64 AsPC-1 Px + Aq 0.60 49 40
Px + Ge 0.67 40 33 Px + Ge + Aq 0.46 65 54
Abbreviations: Aq, Compound 1; Px, paclitaxel; Ge, gemcitabine; TCR, tumor volume of treatment-to-control ratios; TGI, volume of tumor growth inhibition; TIR, tumor weight inhibitory ratio.
[001501 Table 6. Hematological values of .each treatment group in AsPC-1 xenograft study. Table 6. Hematological values of .each treatment group in AsPC-1 xenograft study.
Parameter Unit TI (control) T2 (A) T3 (G,A) T4(P,A) T5 (P, G) T6 (P, G, A) Referens range of 18
WBC 10 91L 6.10±0.83 7.34±0.71 8.92±1.11 8.65±0.64 7.33±1.46 7.65±0.92 4.20-8.86 RBC 10 12L 9.16±1.34 9.93±1.34 9.12 ±0.94 9.05±1.22 9.77±1.43 9.26 ±1.57 7.99-10.83 HGB gIdL 15.5±0.9 15.6±1.1 15.7 ±0.4 14.6 2.9 16.2±1.4 16.1 ±1.9 14.3-16.7 HCT % 51.2±1.6 50.3±1.8 52.1 ±2.1 54.9 ±2.7 53.9±2.1 55.9 ± 3.3 49.0-63.1 MCV fL 54.9±1.7 53.6 ±2.3 57.6 ±4.1 53.1±1.4 56.6 ±4.3 53.1 5.3 53.6 -65.4 MCH pq 1S.10.5 15.310.3 15.510.7 16.1±0.6 16.1±1.1 16.111.9 15.8-16.8
Abbreviations: WBC - white blood count, RBC - red blood cell, HGB - Hemoglobin, HCT Hematocrit, MCV - mean corpuscular volume, MCH - mean corpuscular hemoglobin. Values are means ±SEM (n=3 in each treatment group)
[00151] As shown in the study results, it is clearly shown the superior unexpected benefits utilizing the compositions comprising the exemplary Compound 1 and the current clinical chemotherapy drugs such as paclitaxel and gemcitabine against pancreatic cancer. Cell viability studies showed that the treatments with such combinations resulted in much higher inhibition activity than either Compound 1 or the other chemotherapy drugs alone, suggesting a synergistic and/or additive effect. Such effect was confirmed by the combinations of compound 1 with gemcitabine alone, and with additional paclitaxel which exhibit significant inhibition of tumor growth on tumor bearing mice. Example 3. A Phase I study to determine the maximum tolerated dose (MTD) and to evaluate safety/tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of Compound 1 in combination with nab+paclitaxel+gemcitabine in first line metastatic pancreatic cancer
[00152] Introduction: In 2011, the multidrug combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) was noted to provide an increased median survival of 4.3 months versus gemcitabine; however, given its side effect profile, it is available only to a select group of patients with advanced pancreatic cancer. The patients were randomly assigned to receive FOLFIRINOX or gemcitabine. The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (hazard ratio [HR] for death =0.57; 95% confidence interval [CI], 0.45 to 0.73; p<O.001). Median progression-free survival (PFS) was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression =0.47; 95% CI, 0.37 to 0.59; p<0.001).
[00153] More recently, the gemcitabine plus nab-paclitaxel (the 130-nm albumin-bound nanoparticle formulation of paclitaxel) combination was shown to increase median survival by 1.8 months, with increased OS at 1 and 2 years; adverse effects were reasonable and included cytopenias and peripheral neuropathy. The multi-center, international Phase III MPACT trial included 861 patients with previously untreated metastatic pancreatic adenocarcinoma. The patients were randomly assigned to receive gemcitabine and nab-paclitaxel or gemcitabine monotherapy. The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HR for death=0.72; 95% CI, 0.62 to 0.83; p<0.001). Median PFS was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HR for disease progression=0.69; 95% CI, 0.58 to 0.82, p<0.001).
[00154] The current National Comprehensive Cancer Network recommendations suggest acceptable first-line chemotherapy combinations for patients with good performance status (i.e., Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1), based on patient preference and support system available. These combinations include FOLFIRINOX for patients with better/favorable comorbidity profile, or gemcitabine plus nab-paclitaxel for patients with adequate/acceptable comorbidity profile, nab-paclitaxel+ gemcitabine, and gemcitabine plus erlotinib. Gemcitabine alone is recommended for patients with ECOG PS 2 or with a comorbidity profile that precludes other regimens; the addition of capecitabine or erlotinib may be offered. The guidelines for choosing an appropriate treatment regimen for patients with metastatic pancreatic cancer thus remain ambiguous, and in the absence of a randomized trial comparing the combination regimens head to head, the most appropriate first-line therapy for these patients remains unclear.
[00155] As shown in Example 2, the exemplary compound 1 has shown anti-tumor activity and a low toxicity profile in preclinical in vitro and in vivo animal experiments. In a separate non clinical study using the orthotopic PANC-1 human pancreatic cancer xenograft model with Compound 1 conducted in 2012, four groups of mice were treated with 30 mg/kg, 60 mg/kg, 90 mg/kg, of Compound 1 and vehicle control, respectively to examine the in vivo therapeutic efficacy of Compound 1. Tumor volumes and tumor weights were measured 10 days after drug treatment (19 days after tumor implantation). Treatment with Compound 1 at 30, 60, and 90 mg/kg produced an effective anti-tumor activity with statistically significant smaller mean tumor volumes and tumor weights in all three dosage levels compared to vehicle control. All three doses of antroquinonol were tolerated well by the tumor bearing mice; there was no severe body weight loss observed during the study.
[00156] In the early reported clinical trial studies, Antroquinonol (i.e., Compound 1) at 50, 100, 200, 300, 450, and 600 mg-dose levels, given daily for 4 weeks, was generally safe and well tolerated, as no particular safety concerns or DLTs were identified in this study. The data generated from the safety and pharmacokinetic (PK) profiles in this study could support further studies of antroquinonol in subjects with advanced malignancies to determine the maximum tolerated dose (MTD) and efficacy in given patient populations.
Study Objectives
[001571 The primary objectives of this study are: to determine the MTD or maximum feasible dose (MFD) of Compound 1 in combination with nab+paclitaxel+gemcitabine in subjects with metastatic pancreatic cancer. Although Compound 1 has been assessed for a cancer treatment, it is known in the field that many cancer drugs are less effective in treating metastatic cancer.
[00158] Cohort expansion: to evaluate the anti-tumor activity of antroquinonol in combination with nab+paclitaxel+gemcitabine in subjects with metastatic pancreatic cancer.
[00159] The secondary objectives of this study are:
[00160] Dose escalation: • To evaluate the safety and tolerability of the combination of antroquinonol and nab+paclitaxel+gemcitabine. • To characterize the PK of antroquinonol and nab+paclitaxel+gemcitabine. • To evaluate antroquinonol activity from routine pancreatic cancer monitoring. • To explore the preliminary anti-tumor activity of antroquinonol in combination with nab+paclitaxel+gemcitabine in subjects with metastatic pancreatic cancer.
[00161] Cohort expansion: to evaluate the safety and tolerability of MFD of antroquinonol and nab+paclitaxel+gemcitabine combination; to characterize the PK of antroquinonol and nab-paclitaxel-gemcitabine; to evaluate for antroquinonol activity from routine pancreatic cancer monitoring.
Study Endpoints
[00162] Primary endpoints
[00163] Dose escalation: • Occurrence of DLTs in the 1"28-day cycle of treatment. The DLT definition (grading according to NCI Common Terminology Criteria for Adverse Event [CTCAE] v.4.03): • Non-hematological toxicity of Grade 3 or greater excluding: Grade 3 diarrhea, nausea, or vomiting that resolves within 3 days of onset to Grade 1 or to baseline Grade with appropriate treatment • Grade 4 thrombocytopenia or neutropenia lasting >48 hours • > Grade 3 febrile neutropenia • Grade 3 thrombocytopenia with bleeding * Persisting toxicity of Grade 2 or greater that causes more than a 14 day delay in dose administration.
[00164] AEs that are considered by the Investigator to be related to the underlying disease condition, concomitant medication, or to new unrelated medical events or treatment will not be defined as a DLT.
[00165] Cohort expansion:
[00166] Primary endpoint: To evaluate the anti-tumor activity of antroquinonol in combination with nab+paclitaxel+gemcitabine in subjects with metastatic pancreatic cancer.
[001671 Secondary endpoints:
[00168] Safety: Safety will be evaluated using AEs, physical examinations, laboratory findings (including clinical chemistry, hematology, and urinalysis), vital signs (including blood pressure and pulse), and electrocardiograms (ECGs).
[001691 Efficacy: Objective response rate (ORR), duration of response (DoR), disease control rate (DCR), and PFS using Investigator assessments according to RECIST 1.1 (assessments to occur every 8 weeks), OS.
[00170] Pharmacokinetics: Plasma concentration of antroquinonol and nab+paclitaxel+gemcitabine combination and PK parameters will be evaluated.
[00171] Biomarkers: To evaluate antroquinonol activity from routine pancreatic cancer monitoring.
Investigation Plan
[00172] Overall Study Design and Plan Description
[00173] This is a single-arm, open-label, multi-center Phase I study of Compound 1 in combination with nab-paclitaxel and gemcitabine in first line treatment naive subjects with Stage IV metastatic pancreatic carcinoma.
[00174] The first part of the study will follow a 3+3 dose escalation design to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with standard dose regimen of nab-paclitaxel and gemcitabine. Two dose levels of antroquinonol given TID are planned based on dose escalation data and capsules strengths. The final number of subjects will be based on the number of dose levels investigated and DLTs occurrence. Up to 12 subjects may be treated in this part of the study. A Safety Monitoring Committee (SMC) will be set up for this study to review DLTs and overall safety data and judge the relevance of events to the dose escalation scheme.
[001751 After MTD/MFD determination, enrollment will continue at a fixed dose of antroquinonol (MTD or MFD). A maximum of 40 evaluable subjects is planned in this cohort expansion part of the trial.
[00176] Investigational product, dosage, and mode of administration • Escalating doses of Compound 1 (200 to 300 mg) per oral, TID administration, until unacceptable toxicity or disease progression, and in the absence of discontinuation criteria. • 125 mg/m2 nab-paclitaxel and 1000 mg/m2 gemcitabine via intravenous (IV) infusion, both administered on Days 1, 8, and 15 of each 28-day cycle (ie, 1 cycle = weekly for 3 weeks, then 1 week off) until unacceptable toxicity or disease progression.
[001771 DLT definition and evaluation
[001781 Dose limiting toxicity is defined as the occurrence of any of the toxicities outlined below occurring during the DLT evaluation period that are determined to be related or possibly related to investigational medicinal products (IMP) combination. The DLT evaluation period will be the first 28-day treatment cycle. Toxicity grading will be determined using NCI CTCAE version 4.03. Dose limiting toxicities will be defined as: • Non-hematological toxicity of Grade 3 or greater excluding: - Grade 3 diarrhea, nausea, or vomiting that resolves within 3 days of onset to Grade 1 or to baseline Grade with appropriate treatment. • Grade 4 thrombocytopenia or neutropenia lasting 248 hours S2 Grade 3 febrile neutropenia • Grade 3 thrombocytopenia with bleeding Persisting toxicity of Grade 2 or greater that causes more than a 14 day delay in dose administration.
[001791 AEs that are considered by the Investigator to be related to the underlying disease condition, concomitant medication, or to new unrelated medical events or treatment will not be defined as a DLT.
[00180] Selection of Study Population
[00181] Inclusion Criteria: To be eligible to participate in the study, subjects must meet the following criteria: 1. Male and female subjects >18 years or older. 2. Histologically or cytologically confirmed metastatic ductal adenocarcinoma of the pancreas, measurable according to the RECIST 1.1. 3. Metastatic disease had to have been diagnosed within 6 weeks before randomization. 4. Treatment-naive subjects with metastatic pancreatic ductal adenocarcinoma who have received no previous systemic therapy (except adjuvant or neoadjuvant therapy if progression occurred >6 months from last treatment or surgery, respectively, and no prior nab-paclitaxel). 5. Adequate hematologic, hepatic, and renal
function, including: - Hemoglobin >9 g/dL
- Absolute neutrophil count 1500/mm 3
- Platelet count >100 000/mm 3
- Total bilirubin <1.5 x upper limit of normal (ULN) except subjects
with documented Gilbert's syndrome (>3 x ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) <2.5 x ULN; for subjects with hepatic metastases, ALT and AST <5 x ULN
- Albumin >3 mg/dL
- Serum creatinine <1.5 mg/dL or calculated creatinine clearance >50
mL/min as determined by the Cockcroft-Gault equation
- ECOG of 0 or 1.
6. For women of childbearing potential, a negative serum pregnancy test result at Screening and on Day 1. 7. Willing to use two medically accepted and effective methods of contraception from the list below during the study (both men and women as appropriate) and for 3 months after the last dose of study drug:
- Established use of oral, injected, or implanted hormonal methods of
contraception
- Placement of an intrauterine device or intrauterine system
- Barrier methods of contraception: Condom or Occlusive cap
(diaphrag or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
- Male sterilization (with the appropriate postvasectomy documentation
of the absence of sperm in the ejaculate)
- True abstinence: When this is in line with the preferred and usual
lifestyle of the subject. 8. Signed ICF. 9. Life expectancy >12 weeks.
[00182] Exclusion Criteria: Subjects who meet any of the following criteria will not be eligible to participate in the study: 1. Islet-cell neoplasms or locally advanced disease. 2. Chemo-, hormone-, or immunotherapy or investigational drug within 4 weeks or five half-lives of the date of first administration of study drug (whichever is shorter) and/or persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant. 3. Treatment with any drug(s) known to be a strong inhibitor or inducer of cytochrome P450 (CYP) 2C19, CYP3A4, CYP2C8, and CYP2E1 within 14 days of the date of first administration of study drug and during study treatment. 4. Other malignancies diagnosed within the past five years (other than curatively treated cervical cancer in situ, nonmelanoma skin cancer, superficial bladder tumors Ta [noninvasive tumor] and TIS [carcinoma in situ], or nonmetastatic prostate cancer Stage 1 to 2, which has been previously treated with surgery or radiation therapy, and serum prostate-specific antigen is within normal limits [test performed within the past 12 months prior to the date of first administration of study drug]). 5. Subjects with any serious active infection (ie, requiring an intravenous antibiotic, antifungal, or antiviral agent). 6. Subjects with known human immunodeficiency virus, active hepatitis B, or active hepatitis C. 7. Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise subject safety or interfere with the evaluation of the safety of the study drug. 8. Known or suspected substance abuse or alcohol abuse. 9. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study treatment, or compromise the ability of the subject to give written informed consent. 10. Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea, eg, Crohn's disease, malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline. 11. Female subjects who are pregnant or breastfeeding, or male or female subjects of reproductive potential who are not employing an effective method of birth contraception.
[00183] Withdrawal of Subjects: Subjects may withdraw their consent to participate in the study and investigators may withdraw subjects at any time without prejudice. Subjects will be withdrawn from the study or study treatment if any of the conditions set below has occurred:
1. Documented disease progression according to the response criteria. 2. Unacceptable toxicity. 3. Subject decides to withdraw his/her informed consent. 4. Investigator considers that the subject is no longer physically and/or psychologically able to remain in the study.
[00184] Replacement Procedures:During the dose escalation phase, a subject who does not experience DLTs in the first cycle and who meets any of the following should be replaced with new subject: • All planned trial treatment dosing are not completed in the first 28-day cycle. • All planned trial treatment dosing are completed with/without delay; however, 90% of the planned total dose of either drug is not administered in the first cycle.
[00185] Guidance to Investigators on When to End Study Treatment Regimen: Subjects may withdraw their consent to participate in the study and investigators may withdraw subjects at any time. Subjects will be withdrawn from the study or study treatment if any of the following conditions are met: 1. Lost to follow-up. 2. Any AE or medical condition that the Investigator or Sponsor determines may jeopardize the subject's safety if he or she continues in the study. 3. Pregnancy or intent to become pregnant. 4. Subject noncompliance that, in the opinion of the Investigator or Sponsor, warrants withdrawal from study medication (eg, refusal to adhere to scheduled visits). 5. Initiation of alternative anti-cancer therapy, including another investigational agent. 6. Confirmed progressive disease and Investigator determination that the subject is no longer benefiting from study treatment. 7. The Sponsor terminates the study. Reasons for terminating the study may include, but are not limited to, the following: the incidence or severity of AEs in this or other studies indicates a potential health hazard to subjects; subject enrollment is unsatisfactory.
[001861 Follow-up of Subjects Prematurely Discontinued From the Study Treatment Regimen or Withdrawn From Study:
[001871 All subjects will attend a safety follow-up visit 28 days after receiving the last administration of study treatments. Subjects who discontinue investigational product prematurely will be asked to return to the clinic for an early termination visit and may undergo follow-up assessments. The primary reason for premature investigational product discontinuation should be documented on the appropriate electronic case report form (eCRF).
[00188] Treatment of Subjects
[00189] Treatments Administered: Compound 1 will be administered in 200- to 300-mg doses (planned dose levels), TID, given in 100 mg capsules (resulting a daily dosage of 600 mg to 900 mg). Additional dose levels may be investigated as determined by the study SMC. The study drug will be filled in # 2 capsules (100 mg) and then packed in a light-protected polyethylene bottle and closed with a piece of polyethylene cap liner fitted in the cap for each dispensation at Visit 1 (Day 0), 3 (Day 28), 4 (Day 42), 5 (Day 56), and 6 (Day 84), and subsequent visits for subjects entering the Extension Phase. The study drug will be labeled in accordance with country-specific requirements. Several doses of antroquinonol are planned for the first dose escalation part of the trial. Dose escalation will follow a 3+3 design based on DLT occurrence. The starting dose of antroquinonol will be 200 mg TID, which is the dose currently investigated in the ongoing Phase II single-agent trial in NSCLC. If there are no DLTs or <1/ 6 subjects with DLT, the dose will be escalated to 300 mg TID. One dose (MTD or MFD) will be investigated in the cohort expansion part of the trial.
[00190] Subjects will receive antroquinonol as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria. Antroquinonol should be taken every 8 hours approximately 15 minutes after a meal or light snack and not within ±1 hour of drinking an ethanol-containing beverage, eg, an alcoholic drink. Subjects who forget or are unable to take a dose at the scheduled time should be instructed to take the dose as soon as possible. If they do not remember or are unable to take the dose prior to the next scheduled dose, they should take the scheduled dose and the missed dose will not be made up. The date and time of each study drug administration should be recorded in the subject diary.
[00191] The recommended dose of nab-paclitaxel in combination with gemcitabine is 125 mg/m2 via IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. The concurrent recommended dose (RD) of gemcitabine is 1000 mg/m2 via IV infusion over 30 minutes immediately after the completion of nab-paclitaxel administration on Days 1, 8, and 15 of each 28-day cycle. Treatment with nab-paclitaxel + gemcitabine will continue until unacceptable toxicity or disease progression. Per clinical practice and local regulation, in case of subject toxicity, the Day 15 treatment administration can be omitted. In this case, the start of the subsequent cycle will begin early, on Day 22 of thefirst cycle administration (except for Cycle 1, the DLT period). The tumor assessment schedule will not be altered (ie, assessments will continue to be every 8 weeks).
[00192] Selection and Timing of Dose for Each Subject: In the dose escalation part of the study, subjects will be enrolled and treated sequentially following a 3+3 dose escalation design. In the cohort expansion part, subjects will be enrolled and treated in parallel.
[00193] Efficacy and Safety Variables
[00194] Efficacy Assessments: The RECIST 1.1 criteria will be used to assess subject response to treatment by determining ORR, DoR, DCR, PFS, PFS 3 months, and PFS 6 months. The RECIST 1.1 guidelines for measurable, non-measurable, target, and non-target lesions and the objective tumor response criteria (complete response [CR], partial response [PR], stable disease [SD], or progressive disease) are presented based on revised response evaluation criteria in solid tumors guidelines Version 1.1 - adaptation from original publication with addition of supplementary explanations. The OS, OS 6 months, and OS 12 months will also be evaluated.
[00195] The baseline assessments should be performed no more than 28 days before start of study treatment and ideally should be performed as close as possible to the start of study treatment. Efficacy for all subjects will be assessed by objective tumor assessments every 8 weeks for the first 12 months and every 12 weeks thereafter until confirmed objective disease progression. If an unscheduled assessment is performed and the subject has not progressed, every attempt should be made to perform the subsequent assessments at his or her scheduled visits.
[00196] A confirmatory scan is required following the initial demonstration of progressive disease. The confirmatory scan should occur preferably at the next scheduled visit and no earlier than 4 weeks after the initial assessment of progressive disease in the absence of clinically significant deterioration. Treatment will continue between the initial assessment of progression and confirmation for progression. If a subject discontinues treatment (and/or receives a subsequent anti-cancer therapy) prior to progression, then the subject should still continue to be followed until confirmed objective disease progression.
[001971 Objective tumor response (CR or PR) should be confirmed preferably at the next scheduled visit and not less than 4 weeks after the visit when the response was first observed.
[001981 Following confirmed progression, subjects should continue to be followed up for survival every 2 months (8 weeks). In addition, all subjects will be contacted in the week following data cutoff to confirm survival status.
[00199] Safety Assessments: Safety will be monitored throughout the study for all subjects. The analysis of the safety data will be performed using the Safety Analysis Set.
[00200] Adverse events:
[00201] Definitions: The term "adverse event," as used by the Sponsor, is synonymous with the term "adverse experience," which is used by the FDA.
[00202] An AE is any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study with a Sponsor test article, regardless of causal relationship. This includes the following: • Any clinically significant worsening of a pre-existing condition • Note: Emergence of a new pathogen associated with a clinical event during therapy at a site other than the initial site of infection will be considered to be an AE. • Any recurrence of a pre-existing condition • An AE occurring from overdose of a Sponsor study drug whether accidental or intentional (ie, a dose higher than that prescribed by a health care professional for clinical reasons) • An AE occurring from abuse of a Sponsor study drug (ie, use for nonclinical reasons) • An AE that has been associated with the discontinuation of the use of a Sponsor study drug.
[00203] Note: A procedure is not an AE, but the reason for a procedure may be an AE.
[00204] A pre-existing condition is a clinical condition (including a condition being treated) that is diagnosed before the subject signs the ICF and that is documented as part of the subject's medical history.
[00205] The questions concerning whether the condition existed before the start of the active phase of the study and whether it has increased in severity and/or frequency will be used to determine whether an event is a TEAE. An AE is considered to be treatment-emergent if (1) it is not present when the active phase of the study begins and is not a chronic condition that is part of the subject's medical history, or (2) it is present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increases during the active phase. The active phase of the study begins at the time of the first dose of the study drug. The active phase of the study ends at the follow-up visit.
[002061 Reporting of Adverse Events: At each visit the Investigator, or delegate, will determine whether or not any AEs have occurred. The subject will be questioned in a general way and no specific symptoms will be suggested. If any AEs have occurred, they will be recorded in the AE section of the eCRF and in the subject's medical records. If known, the diagnosis should be recorded, in preference to listing the individual signs and symptoms.
[00207] Adverse event reporting begins from the time of informed consent and ends 30 days after the last dose of IMP.
[00208] Assessment of Severity: The AE severity grading scale for the NCI CTCAE (version 4.03) will be used for assessing AE severity. For AEs that are not specifically listed in the NCI CTCAE, the following definitions will be used: • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. • Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. • Grade 3: Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. • Grade 4: Life-threatening consequences or urgent intervention indicated. • Grade 5: Death related to AE.
[002091 Relationship to Study Treatment: The Investigator will make a determination of the relationship of the AE to the study drug using a four-category system according to the following guidelines: • Unrelated: Clinical event with an incompatible time relationship to drug administration, and that could be explained by underlying disease or other drugs or chemicals or is incontrovertibly not related to the study drug. • Unlikely: Clinical event whose time relationship to drug administration makes a causal connection improbable, but that could plausibly be explained by underlying disease or other drugs or chemicals.
* Possible: Clinical event with a reasonable time relationship to study drug administration, but that could also be explained by concurrent disease or other drugs or chemicals. • Definite: Clinical event with plausible time relationship to study drug administration, and that cannot be explained by concurrent disease or other drugs or chemicals.
[00210] Follow-up of Adverse Events: It is important for the investigators to take information of underlying diseases, concomitant drugs, and temporal relationship of the onset of the event to the time of dosing the study drug, and re-challenging outcomes, into account when making a causal relation decision. It is the Investigators' responsibility to follow proactively the outcome of each AE until resolution or stabilization of the condition, alternative treatment for pancreatic cancer is started, 6 months after last dose of study drug, or loss to follow-up, whichever occurs first. In the event of serious or study drug-related toxicities, the subject will be followed until resolution or stabilization. Safety follow-up data may be collected by telephone contact every 3 months after the End of Study Visit.
[00211] Serious Adverse Events: A serious adverse event (SAE) is any AE occurring at any dose that meets 1 or more of the following criteria: • Results in death • Is life-threatening (see below) • Requires subject hospitalization or prolongation of an existing hospitalization (see below) • Results in a persistent or significant disability or incapacity (see below) • Results in a congenital anomaly or birth defect • Results in an important medical event (see below).
[00212] Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they mayjeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not require hospitalization, or development of drug dependency or drug abuse.
[00213] A life-threatening AE is any AE that places the subject at immediate risk of death from the event as it occurred. A life-threatening event does not include an event that might have caused death had it occurred in a more severe form but that did not create an immediate risk of death as it actually occurred. For example, drug-induced hepatitis that resolved without evidence of hepatic failure would not be considered life-threatening, even though drug-induced hepatitis of a more severe nature can be fatal. Hospitalization is to be considered only as an overnight admission.
[00214] Hospitalization or prolongation of a hospitalization is a criterion for considering an AE to be serious. In the absence of an AE, the participating Investigator should not report hospitalization or prolongation of hospitalization.
[00215] In addition, a hospitalization planned before the start of the study for a pre existing condition that has not worsened does not constitute an SAE (eg, elective hospitalization for a total knee replacement due to a pre-existing condition of osteoarthritis of the knee that has not worsened during the study).
[00216] Disability is defined as a substantial disruption in a person's ability to conduct normal life functions. If there is any doubt as to whether a case constitutes an AE or SAE based on the information available, the case should be treated as an SAE.
[002171 Alternatively, medical and scientific judgment should be exercised in deciding whether a case is serious in those situations where important medical events may not be immediately life-threatening or result in death, hospitalization, disability, or incapacity. These include events that may jeopardize the subject or may require medical intervention to prevent one or more outcomes listed in the definition of serious.
[00218] Pharmacokinetic Analysis
[00219] Noncompartmental PK analyses will be performed on individual plasma concentration data. The PK analyses will be performed using commercial software such as PhoenixTM WinNonlin@ Version 6.4 or higher (Certara USA, Inc.). Maximum plasma concentration (Cmax), trough (predose) concentration (Ctrough), and the time of Cmax (Tmax) will be taken directly from the observed data. The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule. The PK parameters will be listed for each individual and summarized by treatment group using descriptive statistics (sample size [N], arithmetic mean, standard deviation, coefficient of variation [CV%], median, minimum, maximum, and geometric mean). Individual concentration data will be listed and summarized by treatment group with descriptive statistics (N, arithmetic mean, standard deviation, median, minimum, maximum, geometric mean, and CV%). Mean and individual plasma concentration time profiles will be presented graphically on both linear and semilogarithmic scales.
[002201 Actual dose administration times and sample collection times will be used for the analyses as recorded on the case report form. Plasma concentrations below the lower limit of quantification will be set to zero for the analysis. Pharmacokinetic parameter estimates will be three or four significant figures for presentation. No attempt will made to estimate missing data. Other parameters and data handling procedures may be added as appropriate. Only subjects who are given active antroquinonol and have evaluable concentration-time profiles will be included in the analysis. All statistical analyses will use nonrounded parameter estimates.
[00221] A population PK (PopPK) model development and analysis may be performed using mixed-effects methods. Dosing, sampling, demographic, and laboratory data from each subject will be assembled into a database suitable for a population analysis. A nonlinear mixed effects model will be developed using NONMEM (Globomax, Ellicot City, MD). Various structural models will be evaluated as indicated by the data. Covariate effects (age, gender, race, body size, smoking history, etc.) will be evaluated and incorporated into the model using univariate or multivariate approaches. Once the optimal model has been established, it will be validated using standard methods, such as visual predictive checks and bootstrap analyses.
[00222] The potential exposure-exposure/concentration relationships could be evaluated based on the post hoc estimates of antroquinonol exposure (ie, model predicted Cmax, Ctrough, and AUC,) from the above PopPK model or the concentration observations.
[00223] Statistical Methods
[00224] General Consideration: For study reporting purposes the following aspects will be considered: • Descriptive statistics and graphical presentations will be the main analysis tools. • Subject disposition will be reported for each dose level using the All Subjects Set for both Phases of studies, and subject profiles will be presented for the dose escalation phase of the study only. * For all analyses, results, and graphical representation of individual subject data will be presented by dose level. The dose level to which a subject was assigned at the first treatment will be indicated on all outputs.
[00225] Descriptive statistics and graphical representations will be used to summarize the data for each dose level. The following summary statistics will be used to summarize the trial data per dose level based on their nature, unless otherwise specified: • Continuous variables: number of nonmissing observations (N), mean, standard deviation, median, minimum, and maximum; 95% CI will be presented where appropriate. Categorical variables: frequencies and percentages.
[00226] Details of the statistical analysis will be presented in the Statistical Analysis Plan.
[002271 Efficacy Analysis
[00228] Primary Outcome Measures:
[00229] Dose escalation phase: The number and proportion of subjects experiencing DTLs in each dose level during Cycle 1 will be assessed on the DLT Analysis Set.
[00230] Cohort expansion phase: Descriptive summary of subjects with best overall response in each category (CR, PR, SD, and progressive disease); the objective response rate (CR+PR); the disease control rate (CR+PR+SD [SD of >16 weeks]) with 95% CIs according to RECIST 1.1 will be performed on Efficacy Analysis Set.
[00231] Criteria in Solid Tumors (RECIST) version 1.1 will be performed for median OS time and PFS time with 95% CI will be evaluated using Kaplan-Meier methods on Full Analysis Set. The OS is defined as the time from first dose of study drug to subject death. The PFS is defined as the time from first dose of study drug to the start of disease progression or subject death, whichever occurred first.
[00232] Analysis of Secondary Outcome Measures: Data of secondary endpoints will be listed by dose level, subject, and visit (if applicable). Secondary endpoints will be descriptive analyzed by dose level in the relevant analysis set.
[00233] Safety and Tolerability Analysis: The number and proportion of subjects experiencing TEAEs; drug exposure; clinically significant changes in laboratory parameters, vital signs, physical examinations, weight, ECOG performance status, ECGs, and/or pulse oximetry, judged to be related to the trial medication; and number and reasons of deaths will be summarized.
[00234] Safety evaluation will include incidence of AEs (or TEAEs), laboratory test results, vital signs, ECG results, and physical examination findings. All summaries of safety data will be based on the Safety Analysis Set. No formal statistical analysis of the safety data will be performed.
[00235] Summary tables will be presented for all Adverse Effects (AEs) by dose level and Medical Dictionary for Regulatory Activities SOC and preferred term where applicable. The incidence and type of the following AEs will be analyzed.
[00236] An AE will be considered as "treatment-emergent" if it occurred after the first study treatment or if it occurred before thefirst study treatment and worsened thereafter.
[002371 The TEAE summary tables will include counts of subjects. Therefore, if a subject experiences more than one episode of a particular AE, the subject will be counted only once for that event. If a subject has more than one AE that is coded to the same preferred term, the subject will be counted only once for that preferred term. Similarly, if a subject has more than one AE within an SOC, the subject will be counted only once in that SOC.
[002381 All deaths and deaths within 30 days of the last dose of study treatment as well as reasons for death will be tabulated by dose level. Drug exposure will be summarized by dose level.
[002391 Clinically significant laboratory test variables will be summarized by dose level and visit (if applicable) using descriptive statistics (number of subjects, mean, standard deviation, minimum, maximum, as well as mean change from baseline, standard deviation for mean and standard error for mean change, minimum, median, maximum, and number and percent of subjects within specified categories). Shift tables (ie, cross-tabulations of below the lower limit of the normal range, within the limits of the normal range and above the upper limit of the normal range at baseline versus scheduled visits) will be presented by laboratory test (if applicable). Laboratory tests with categorical results that cannot be analyzed by change from baseline or shift table analysis will not be included in these summaries, but will be listed. Data obtained from laboratory tests not required by the protocol will not be summarized, but will be listed.
[00240] Descriptive statistics of vital signs, weight and ECG results at each visit will be presented by treatment group. Physical examination findings will be listed for each subject. The overall response rate and the DCR will be estimated along with 95% CIs calculated using the method of Clopper and Pearson by dose level.
[00241] Pharmacokinetic Analysis
[00242] Pharmacokinetic Sampling: The PK sampling will be performed on Day 0 and Day 28 in all subjects enrolled in the first stage at the following time points: * Day 0: (Approximately 5 mL per sample, 60 mL in total) 30 minutes prior to and 0.5, 1, 2, 3, 4, 6, and 8 hours after the first dose. * Day 28: (Approximately 5 mL per sample, 60 mL in total) immediately before and 0.5, 1, 2, 3, 4, 6, and 8 hours after the first dose on Day 28.
[00243] Sparse PK sampling will be performed on Days 28, 42, and 56 in all subjects enrolled in Stage 2. At least two samples will be collected on each occasion, one of which will be a trough concentration (30 minutes prior to the first dose on Days 28, 42, and 56 and approximately 8 hours after the last dose on the prior day). At least one sample per subject will be timed to coincide with the peak concentration (3 hours after the first dose). The remainder may be taken at any time during the dosing interval.
[00244] Each blood sample will be analyzed for antroquinonol plasma concentration to determine PK parameters after administration of antroquinonol using a fully validated bioanalytical method (a copy of the analytical method validation report and bioanalytical report will be included in the clinical study report).
[00245] Pharmacokinetic Sampling Procedures
[00246] Blood Samples: Samples of venous blood will be obtained in 5 mL sodium heparin Vacutainer@ tubes at the pre-scheduled sample times. Immediately after collection the tube will be gently inverted 8 to 10 times to mix the anticoagulant with the blood sample. All samples will be processed and placed into a freezer within one (1) hour after collection. The plasma fraction will be separated by placing the collection tube into a refrigerated centrifuge (4°C) for 10 minutes at 3000 rpm. The plasma fraction will be withdrawn by pipette and divided into two polypropylene freezing tubes (with each tube receiving approximately equal aliquots). All sample collection and freezing tubes will be clearly labeled with the subject number, the study period, and the collection time. Labels will be fixed to freezing tubes in a manner that will prevent the label from becoming detached after freezing. All plasma samples will be placed into a freezer at °C within 1 hour after collection.
[002471 Analytical Methodology: The concentration of study drug will be determined from the plasma samples using a validated analytical method. Details of the method validation and sample analysis will be included in the final clinical study report.
[00248] Preliminary Results:
[00249] The preliminary results from the patients with 600 mg daily dosage shows that the patient tumor size (mm) reduced after the completion of the 3 rd cycle (8 weeks treatment). One patient's tumor size reduced 7.6% from 91 mm to 84 mm, and the other patient's tumor size reduced 22% from 50 mm to 39 mm. The preliminary tumor size reduction further supports the superior unexpected benefits of the invention compositions comprising the exemplary Compound 1 and the current clinical chemotherapy drugs such as paclitaxel and gemcitabine against pancreatic cancer as shown in the animal study.
[00250] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (8)
1. A method for treating pancreatic cancer in a subject comprising administering to the subject a compound having the structure:
CH 3 CH 3 CH 3 CH 3 0 /// CH3 H3CO OH 0 CH3
and one or more anti-cancer agents to wherein the one or more anti-cancer agents is erlotinib, 5-FU, oxaliplatin, irinotecan, gemcitabine, paclitaxel, or a combination thereof, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the one or more anti-cancer agents is gemcitabine, paclitaxel, or a combination thereof.
3. The method of claim 1, further comprising an immunotherapy agent.
4. The method of claim 1, wherein said compound, or a pharmaceutically acceptable salt, is administered orally, parenterally, intravenously or by injection.
5. The method of claim 1, wherein said medicament further comprises an immunotherapy agent.
6. Use of a therapeutically effective amount of a compound having the structure:
CH 3 CH 3 CH 3 CH 3 0 CH 3 H3C'O OH
Os CH3 or a pharmaceutically acceptable salt, thereof, in the manufacture of a medicament for treating a patient whose pancreatic cancer is resistant, refractory or non-responsive to gemcitabine, paclitaxel, or a combination thereof.
7. The use of claim 6, wherein said compound, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, is administered orally, parenterally, intravenously or by injection.
8. The use of claim 6, wherein said medicament further comprises an immunotherapy agent.
Dated this 1 8 th day of September 2023 Spruson & Ferguson Pty Ltd Attorneys for: Golden Biotechnology Company
FIG. 1A-B
FIG. 2A-B
FIG. 3A-B
FIG. 4A-B
FIG. 5A-B
FIG. 6A-B
FIG. 7A-B
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608549P | 2017-12-20 | 2017-12-20 | |
US62/608,549 | 2017-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2018247249A1 AU2018247249A1 (en) | 2019-07-04 |
AU2018247249B2 true AU2018247249B2 (en) | 2023-10-19 |
Family
ID=66948249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018247249A Active AU2018247249B2 (en) | 2017-12-20 | 2018-10-10 | Therapeutic compositions for treating pancreatic cancer |
Country Status (5)
Country | Link |
---|---|
JP (2) | JP7373824B2 (en) |
KR (1) | KR102620231B1 (en) |
AU (1) | AU2018247249B2 (en) |
CA (1) | CA3020933C (en) |
TW (1) | TW201927736A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101343247A (en) * | 2007-07-12 | 2009-01-14 | 国鼎生物科技股份有限公司 | Cyclohexenone extract of Antrodia camphorata |
US20110009494A1 (en) * | 2009-07-09 | 2011-01-13 | Golden Biotechnology Corporation | Inhibition of the Survival of Pancreatic Cancer by Cyclohexenone Compounds from Antrodia Camphorata |
CN102000046A (en) * | 2009-09-02 | 2011-04-06 | 国鼎生物科技股份有限公司 | Antrodia camphorata cyclohexenone compound for inhibiting growth of pancreatic cancer tumor cells |
US20150018296A1 (en) * | 2013-03-15 | 2015-01-15 | Golden Biotechnology Corporation | Therapeutic methods and compositions utilizing cyclohexenone compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI612026B (en) | 2013-02-20 | 2018-01-21 | 國鼎生物科技股份有限公司 | Cyclohexenone compositions and process for making thereof |
-
2018
- 2018-10-10 AU AU2018247249A patent/AU2018247249B2/en active Active
- 2018-10-11 JP JP2018192916A patent/JP7373824B2/en active Active
- 2018-10-15 CA CA3020933A patent/CA3020933C/en active Active
- 2018-10-16 KR KR1020180123192A patent/KR102620231B1/en active IP Right Grant
- 2018-10-16 TW TW107136260A patent/TW201927736A/en unknown
-
2023
- 2023-07-13 JP JP2023115450A patent/JP2023134664A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101343247A (en) * | 2007-07-12 | 2009-01-14 | 国鼎生物科技股份有限公司 | Cyclohexenone extract of Antrodia camphorata |
US20110009494A1 (en) * | 2009-07-09 | 2011-01-13 | Golden Biotechnology Corporation | Inhibition of the Survival of Pancreatic Cancer by Cyclohexenone Compounds from Antrodia Camphorata |
CN102000046A (en) * | 2009-09-02 | 2011-04-06 | 国鼎生物科技股份有限公司 | Antrodia camphorata cyclohexenone compound for inhibiting growth of pancreatic cancer tumor cells |
US20150018296A1 (en) * | 2013-03-15 | 2015-01-15 | Golden Biotechnology Corporation | Therapeutic methods and compositions utilizing cyclohexenone compounds |
Also Published As
Publication number | Publication date |
---|---|
JP2019112389A (en) | 2019-07-11 |
KR102620231B1 (en) | 2024-01-02 |
CA3020933A1 (en) | 2019-06-20 |
TW201927736A (en) | 2019-07-16 |
KR20190074946A (en) | 2019-06-28 |
JP2023134664A (en) | 2023-09-27 |
AU2018247249A1 (en) | 2019-07-04 |
CA3020933C (en) | 2024-05-14 |
JP7373824B2 (en) | 2023-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6929785B2 (en) | Compositions and methods for the treatment of anemia | |
EA034512B1 (en) | Treatment of cancer with tor kinase inhibitors | |
KR20200016407A (en) | Use of cxcr4 antagonists | |
WO2013184621A1 (en) | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease | |
US20220133675A1 (en) | Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia | |
CN105813637A (en) | Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome | |
AU2018247249B2 (en) | Therapeutic compositions for treating pancreatic cancer | |
US11406605B2 (en) | Therapeutic compositions for treating pancreatic cancer | |
WO2022036111A1 (en) | Methods and compositions for treating sickle cell disease | |
AU2017261826B2 (en) | Methods and compositions for treating advanced stage non-small cell lung cancer | |
US9913846B2 (en) | Combination of a PI3 kinase inhibitor with pacitaxel for use in the treatment or prevention of a cancer of the head and neck | |
KR20180006417A (en) | His use for cabbage taxa and cancer treatment | |
US20220378776A1 (en) | Drug combination of quinoline derivative and pd-1 monoclonal antibody | |
CN116761610A (en) | AHR inhibitors and uses thereof | |
TW202102211A (en) | Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |